METHOD FOR TREATING HIV AND OTHER RETROVIRUSES AND COMPOUNDS USEFUL THEREFOR

Abstract: The present invention relates to a method of inhibiting a retrovirus in a mammalian cell infected with said retrovirus which comprises treating said cell with an effective amount of a compound of formula (I): X-C8-D9-E10-F11-G12-Z. The present invention also provides novel compounds useful in this method.

Description: METHOD FOR TREAΗNG HIV AND OTHER RETROVIRUSES AND COMPOUNDS USEFUL THEREFOR FIELD OF THE INVENTION The present invention relates to a method of inhibiting a retrovirus in a human cell infected with said retrovirus which comprises treating said cell with an effective amount of a retroviral proteinase inhibitory compound of formula I. The present invention also provides novel compounds which are useful in this method. BACKGROUND OF THE INVENΗON An estimated one to one and one-half million people in the United States are infected with a human retrovirus, the human immunodeficiency virus type I, HTV-1, which is the etiological agent of acquired immunodeficiency syndrome, AIDS (C. Norman, Science, 661-662 (1986)). Of those infected, an estimated two hundred and fifty thousands people will develop AIDS in the next five years (J.W. Curran, et al., Science, 1352-1357 (1985)). On March 20, 1987, the FDA approved the use of the compound, zidovudine (AZT), to treat AIDS patients with a recent initial episode of pneumocystis carinii pneumonia, AIDS patients with conditions other than pneumocystis carinii pneumonia or patients infected with the virus with an absolute CD4 lymphocyte count of less than 200/mm 3 in the peripheral blood. AZT is a known inhibitor of viral reverse transcriptase, an enzyme necessary for human immunodeficiency virus replica- tion. U.S. Patent 4,724,232 claims a method of treating humans having acquired immunodeficiency syndrome utilizing 3'-azido-3'-deoxy-thymidine (azidothymidine, AZT). Since the first description of the malady in the early part of this decade, acquired immunodeficiency disease syndrome (AIDS) and its devastating consequences have been subjects of continuous and intense coverage in both the lay and scientific press. Indeed, a recent edition of Scientific American was entirely devoted to AIDS (Scientific American 289, #4 (1988)), and the literature on the disease and the virus is already so vast as to defy thorough citation. At present, there is no effective treatment of the disease, and 3'-azido-3'-deoxythymidine (AZT), an inhibitor of the viral reverse transcriptase (RT) remains the therapy of choice, despite its highly toxic side effects. Human immunodeficiency virus (HIV) has long been recognized as the causative agent in AIDS, although a minority opinion to the contrary has been expressed (e.g., P. Duesberg, Proc. Natl. Acad. Sci., USA, 86:755-764 (1989)). Sequence analysis of the complete genomes from several infective and non-infective HIV-isolates has shed considerable light on the make-up of the virus and the types of molecules that are essential for its replication and maturation to an infective species (L. Ratner, et al., Nature, 313:277-284 (1985)). HIV exhibits the same gag/pol/env organization seen in other retroviruses (L. Ratner, et al., Nature, 313:277-284 (1985)); S. Wain-Hobson, et al., Cell, 40:9-17 (1985); R. Sanchez-Pescador, et al., Science, 227:484-492 (1985); and M.A. Muesing, et al., Nature, 313: 450-458 (1985)). Reverse transcriptase (RT) is an enzyme unique to retroviruses that catalyzes the conversion of viral RNA into double stranded DNA. Blockage at any point during the transcription process, by AZT or any other aberrant deoxynucleoside triphosphate incapable of elongation, should have dramatic consequences relative to viral replication. Much work on the RT target is in progress based, in large measure, upon the fact that nucleosides like AZT are easily delivered to cells. However, the inefficiency of phosphorylation steps to the triphosphate, and the lack of specificity and consequent toxicity, constitute major drawbacks to use of ACT and similar nucleosides having a blocked, or missing, 3'hydroxyl group. The T4 cell receptor for HTV, the so-called CD4 molecule, has also been targeted as an intervention point in AIDS therapy ( .A. Fisher, et al. , Nature, 331:76-78 (1988); R.E. Hussey, et al., Nature, 331:78-81 (1988); and K.C. Deen, et al., Nature, 331:82- 84 (1988)). The exterior portion of this transmembrane protein, a molecule of 371 amino acids (sCD4) has been expressed in Chinese hamster ovary (CHO) cells and Genentech ( D.H. Smith, et al., Science, 238:1704-1707 (1987)) has had a product in clinical trials since the fall of 1987. Thus far, little information on efficacy is available beyond the fact that the recombinant sCD4 appears to be relatively non-toxic. The idea behind CD4 based therapy is that the molecules can neutralize HTV by interfering with viral attachment to T4, and other cells which express CD4 on their surfaces. A variant on this theme is to attach cell toxins to CD4 for specific binding and delivery to infected cells which display glycoprotein gp-120 on their surfaces ( M.A. Till, et al., Science, 242:1166-1168 (1988); and V.K. Chaudhary, et al., Nature, 335:369-372 (1988)). Another therapeutic target in AIDS involves inhibition of the viral protease (or proteinase) that is essential for processing HIV-fusion polypeptide precursors. In HTV and several other retroviruses, the proteolytic maturation of the gag and gag/pol fusion polypeptides (a process indispensable for generation of infective viral particles) has been shown to be mediated by a protease that is, itself, encoded by the pol region of the viral genome (Y. Yoshinaka, et al., Proc. Natl. Acad. Sci. USA, 82:1618-1622 (1985); Y. Yoshinaka, et al., J. Virol., 55:870-873 (1985); Y. Yoshinaka, et al., J. Virol., 57:826- 832 (1986); and K. von der Helm, Proc. Natl. Acad. Sci., USA, 74:911-915 (1977)). The protease (or proteinase), consisting of only 99 amino acids, is among the smallest enzymes known, and its demonstrated homology to aspartyl proteases such as pepsin and renin ( L.H. Pearl and W.R. Taylor, Nature, 329: 351-354 (1987); and I. Katoh, et al., Nature, 329:654-656 (1987)), led to inferences regarding the three-dimen- sional structure and mechanism of the enzyme (L.H. Pearl and W.R. Taylor, Nature, 329:351-354 (1987)) that have since been borne out experimentally. Active HTV protease has been expressed in bacteria (see, e.g., P.L. Darke, et al., J. Biol. Chem., 264:2307-2312 (1989)) and chemically synthesized ( J. Schneider and S.B. Kent, Cell, 54:363-368 (1988); and R.F. Nutt, et al., Proc. Natl. Acad. Sci., USA, 85:7129-7133 (1988)). Site directed mutagenesis (P.L. Darke, et al., J. Biol. Chem., 264: 2307-2312 (1989); and N.E. Kohl, et al., Proc. Natl. Acad. Sci., USA, 85:4686-4690 (1988) and pepstatin inhibition (P.L. Darke, et al., J. Biol. Chem., 264:2307-2312 (1989); S. Seelmeier, et al., Proc. Natl. Acad. Sci., USA, 85:6612-6616 (1988); C.-Z. Giam and I. Borsos, J. Biol. Chem., 263:14617-14720 (1988); and J. Hansen, et al., EMBO J., 7: 1785-1791 (1988)) have provided evidence for HIV protease's mechanistic function as an aspartyl protease. A recent study has demonstrated that the protease cleaves at the sites expected in peptides modeled after the regions actually cleaved by the enzyme in the gag and pol precursor proteins during viral maturation (P.L. Darke, et al., Biochem. Biophys. Res. Communs., 156:297-303 (1988)). X-ray crystallographic analysis of the HIV-protease (M.A. Navia, et al. , Nature, 337:615-620 (1989)) and a related retroviral enzyme from Rous sarcoma virus (M. Miller, et al., Nature, 337:576-579 (1989)) reveal an active site in the protease dimer that is identical to that seen in other aspartyl prote¬ ases, thus supporting the supposition (L.H. Pearl and W.R. Taylor, Nature, 329:351-354 (1987)) that the HIV enzyme is active as a dimer. To date, an effective means of inhibiting retroviruses in a human hosting such a virus, and thereby effectively treating diseases caused by such a virus, such as acquired immunodeficiency syndrome (AIDS), has not been found. INFORMATION DISCLOSURE The inhibition by relatively high concentrations of pepstatin A (100 μM), a general aspartyl proteinase inhibitor, of HIV replication in H9 cells is described in K. Von der Helm, et al., FEBS Letters, 247:349 (1989). Great Britain 2,203,740 (Sandoz) claims the use of rerun inhibitors for treating diseases caused by retroviruses. A.D. Richards, et al., FEBS Letters, 247:113 (1989) disclose tBoc-His-Pro-Phe- His-LVA-Ile-His, a potent inhibitor of another aspartyl protease human renin, which also contains a hydroxyethylene isotere, inhibits the HIV-1 protease in vitro. Recent information from Smith-Kline-Beecham researchers has described work on the inhibition of HTV-1 replication in cell culture with synthetic protease inhibitors. Int. AIDS Symposium, Montreal, Canada, June 1989 The following patent applications disclose peptides that are useful as inhibitors of renin and retroviral proteases: International Application, Serial No. PCT/US89/- 01672, filed 24 April 1989; U.S. Patent Application, Serial No. 07/405,691, filed 11 September 1989; International Application, Serial No. PCT/US90/03754, filed 9 July 1990; and U.S. Patent Application, Serial No. 07/573,110, filed 24 August 1990. European Published Application 0 357 332 discloses the use of renin inhibitors for the treatment of AIDS by inhibition of HTV protease. These inhibitors may have a moiety of the formula R, 2 R 2 b -X-C(O)- at the N-terminus, wherein X is -O-, -S-, -CH-, or -NHCH-, and wherin R, 2 and R 2 b are the same or different and are hydrogen, C w alkyl, unsubstituted or substituted aryl, and unsubstituted and substituted C 37 -cycloalkyl. However, this application does not disclose diol moieties as the transition state insert. European Published Application 0 352 000 discloses retroviral protease binding peptides, having a variety of moieties as the transition state insert, including alcohols and diols, and having such substituents as t-butyloxycaibonyl, benzyloxycarbonyl and R"C(O)-, wherein R" is hydrogen or C Mg alkyl, at the N-terminus. European Published Application 0 369 141 discloses specific peptides which are useful for inhibiting retroviral proteases. However, these peptides differ from the peptides of the present invention by having a 0-alanine t the Deposition, statine analogs at the transition state insert or N-4-amino-2-methyl-5-pyrirn_dinylmethyl amide at the C- terminus. European Published Applications 0337714 and 0356223 disclose HIV protease inhibitors which do not have an amino acid analog at the D-9 position in front of the transition state insert. SUMMARY OF THE INVENTION The present invention particularly provides: Use of a compound of formula I X-Cg-D 9 -E 10 -F n -Gi 2 -Z I to prepare a medicament for inhibiting a retrovirus in a mammalian cell infected with said retrovirus; wherein X is a) -(CH^-aryl, b) -(CH^-Het, c) -(CHz Ca-CrCycloalkyl, e) R 5 -CH 2 -O-C(O)-, f) Rs-O-C(O)-, g) RHCH -QO)-, h) R 5 -(CH 2 ) n -C(S)-, i) R 4 N(R 4 )-(CH 2 ) n -C(O)-, j) R 5 -SO 2 -(CH 2 ) q -C(O)-, k) R 5 -SO 2 -(CH 2 ) q -O-C(O)-, 1) RHCH -SO 2 , m) Z-C(O)-CH(OH)-CH(CH 2 R,)-C(O)- n) Rs-iCH CH=CH-(CH 2 ) p -C(0)-, p) R^CH^- O)-; wherein C g is absent or a divalent moiety of the formula XL,, XL 2 , XLj,, XL^, or other amino acyl derivative; wherein D 9 is a divalent moiety of the formula XL 3 , XL 2 ,, XL-, or other amino acyl derivative; wherein π, HI, or IV; wherein G 12 is absent or a divalent moiety of the formula XL*, XL^ or other amino acyl derivative; wherein Z is wherein at each occurrence is the same or different as is v) -SO 3 H; wherein R 20 is a) hydrogen, b) C r C 5 alkyl, or c) aryl-C r C 5 alkyl; wherein R 2 , is a) -NH 2 , or b) -OH; wherein R JJ is a) hydrogen, or b) Ci- alkyl; wherein R_ 3 is a) -(CH -OH, b) -(CH 2 ) n -NH 2 , c) aryl, or d) Cr alkyl; wherein R^, is a) -R„ b) -(CH^-OH, or c) -(CH^-NH,; wherein R^ is a) -(CH^-R , b) hydrogen, c) Ci- alkyl, or d) phenyl-Ci-Caalkyl; wherein R M is a) hydrogen, b) Cr alkyl, or c) phenyl- -Caalkyl; wherein R^ is a) -COOH, b) -COOC,-C 6 alkyl, c) -CONRHR M , or wherein R 123 is a) C,-C 5 alkyl, or b) -(CH^-phenyl; wherein R 126 is a) hydrogen, or b) (CH 2 ) n OR J21 ; wherein Rι g is a) hydrogen, or b) -(CHOR 12I ) t CH 2 OR 121 ; wherein Q is a) CH 2 , b) CHOR, 2 „ or c) C(O); wherein j is one to three, inclusive; wherein m is one or two; wherein p is zero to two, inclusive; wherein r is zero to five, inclusive; wherein for each occurrence n is independently an integer of zero to five, inclusive; wherein q is an integer of one to five, inclusive; wherein u is an integer of zero to three, inclusive; wherein v is an integer of zero to four, inclusive; wherein s is an integer of zero or one so that the sum of u plus v plus s is three or four; wherein t is an integer of zero to three, inclusive; wherein w is an integer of two or three; wherein x is an integer of two to seven, inclusive; wherein y is an integer of zero to six, inclusive; and wherein z is an integer of zero to six so that the sum of y plus z does not exceed six; wherein aryl is phenyl or naphthyl substituted by zero to three of the following: a) - alkyl, b) hydroxy, c) Cx- alkoxy, d) halo, e) amino, f) mono- or di-Cj-C 3 alkylamino, g) -CHO, h) -COOH, i) COOR*, j) CONHR , k) nitro, 1) mercapto, m) Cj-Cjalkylthio, n) - alkylsulfinyl, o) Ci- alkylsulfonyl, q) -SO 3 H, r) SOj H,, s) -CN, or t) -CH 2 NH 2 ; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle and the ring may be connected through a carbon or secondary nitrogen in the ring or an exocvclic nitrogen; and if chemically feasible, the nitrogen and sulfur atoms may be in the oxidized forms; and optionally substituted by zero to three of the following: / a) C,-C 3 alkyl. 5 b) hydroxy, c) hydroxy (C,-C . ,alkyl), d) halogen, e) amino, f) amino (C C 5 alkyl), 10 g) -CHO, h) -CC^H, i) -CO 2 -(C r C 5 alkyl), j) -CONH 2) k) -CONH-(C,-C 5 alkyl), 15 1) nitro, m) mercapto, n) mercapto (C r C 5 alkyl), 0) -SO 3 H, p) -SO 2 NH 2 , 20 q) -CN, r) -O-C,-C 5 alkyl, or s) -[O-(CH 2 ) 2 ] n -OCH 3 . with the provisos that: 1) G 12 is present when both C g and D 9 are present and E 10 -F π is other than 25 LPA; 2) when X is Z-C(0)-CH(OH)-CH(CH 2 R,)-C(O)-, D 9 is His and G 12 is Be; 3) when X is R 5 -CH 2 -O-C(O)-or R 5 -(CH 2 ) n -C(O)- and E, 0 - F n is XL* XLβ b , XL f c or XL^, R 5 is other than C,-C 6 alkyl; 4) when X is R 5 -O-C(O)- and E, 0 -F n is XL XL^, XL & 30 or XL*,, R 5 is other than C,-C 6 alkyl, C 3 -C 7 cycloalkyl or aryl; 5) when X is R 5 -(CH 2 ) n -C(O)-wherein R 5 is cycloalkyl or aryl, and E 10 F„ is XL* XL fb , XL & or X ^, n is other than one; 6) when X is R 4 N(R 4 )-(CH 2 ) n -C(O)- and E 10 -Fι, is XL XL*,, XL* or XL & ,, n is other than one; 7) Z is other than N-4-amino-2-methyl-5-pyrimidinγlmethyl-amide; 8) X is other than benzyloxycarbonyl or butyloxycarbonyl, when E IP -F π is II or IV; and 9) when X is K r ( Αj) B ~C(0)- and E I0 -F„ is II or IV, R, is other than C,-C 6 alkyl; and Use of a compound selected from the group consisting of; L-Isoleucinamide, N 2 -(5-amino-4-hydroxy-2-(l-methylethyl)-l-oxooctyl]-N-(2- pyridinylmethyl)-, trifluoroacetate, (S,S,S)-; or H-LVA-Ile-Amp; Octanamide, 5-[(3,3-dimethyl-l-oxobutyl)amino]-4-hydroxy-7-methyl-2-(l- methylethyl)-N-[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]{2S-[l(lR*,2R- *).2R*,4R*,5R*]]- or TBA-LVA-Ile-Amp; Cyclohexanehexanamide, δ-[(3,3-dimethyl-l-oxobutyl)amino]-τ-hydroxy-c_-(l- methylethyl)-N-[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]-, [αS-[N(lR*,2R- *),αR*,τR*,δR*]]- or TBA-CVA-Ile-Amp; Cyclohexanehexanamide, δ-amino-τ-hydroxy-c_-(l-methylethyI)-N-[[2-methyl-l- [[(2-pyridinylme yl)]amino]carbonyl]butyI]- ihydrσchloride,[αS-[N(lR*,2R*),c-R J,t ,τ- R*,δR*]]- or H-CVA-Ile-Amp; Cyclohexanehexanamide, δ-(acetylamino)-τ-hydroxy- -(l-methylethyl)-N-[2- methyl-l-[[( yridinylmethyl)amino]carbonyl]butyl], [αS-[N(lR* ? 2R*),c-R*,τR*,δR !,t ]]-; or Ac-CVA-Ile-Amp; Octanamide^-(acetylamino)-4-hydroxy-7-methyl-2-(l-methyle_hyl)-N-[2-methyl- l-[[(2-pyridinylmethyl)amino)carbonyl]butyl]-, [2S-[N(1R*,2R*),2R*,4R*,5R*]]-, monoacetate (salt); or Ac-LVA-He-Amp; or IYA-LVA-Ile-Amp. Boc-Phe-His-Cha psi[CHOHCHOH]Val-Ile-Amp; or L-Histidinamide, N-[(l,l- dimethylethoxy)carbonyl]-L-phenylalanyl-N-[l-(cyclohexylmethyl)-2,3-dihydroxy-5- memyl-4-[[[2-memyl-l-[[(2-pyridinyimethyl)am_no]car )nyl]butyl]aπ no]carbonyl] , [1S-[1R*,2S*,3S*,4S*(1R*,2R*)]]-; or BOC-Phe-His-CVD-Ile-Amp; L-Histidinamide, N-[(l,l-dimemylethoxy)caιbonyl]-L-phenylalanyl-N-[2-hydroxy- l-(2-memylpropyl)-5-[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino--5- oxo-4-(phenylmethyl)pentyl]-, [1S-[1R*,2R*,4S*,5(1R*,2R*)]]-; or Boc-Phe-His-LPA- Ile-Amp; L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[4- (cyclohexylmethyl)-2-hydroxy-l-(2-methylpropyl)-5-[[2-methyl-l-[[(2-pyridinylmethyl)- amino]carbonyl]butyl]amino]-5-oxopentyl]-, [1S-[1R*,2R*.4S*,5(1R*,2R*)]]-: or Boc- Phe-His-LCA-Ue-Amp; L-Talonamide,6-cyclohexyl-2,5,6-trideoxy-5- N-[N-[(l . l-dimethylethoxy)carbo- nyl]-L-phenylaianyl]-L-histidyI]amino]-2-(l-methylethyl)-N-[2-methyl-l-[[(2-pyridinylmet- hyl)amino]carbonyl]butyl]-, [S-(R*,R*)]-; or Boc-Phe-His-CVD'-Ile-Amp; L Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N-(2,3-dihydroxy-5- methyl- 1 -(2-methylpropyl)-4-[[(2-methyl- 1 -[[(2-pyridinylmethyl)amino]carbonyl]butyl]am- ino]carbonyl]hexyl]-, [1S-[1R*,2S*,3R*,4S*(1R*,2R*)]]-; or Boc-Phe-His-LVDA' -He- Amp; L-HistidinamideN-[[5-(dimethylamino)-l-naphthalenyl]sulfonyl]-L-phenylalanyl- N-[2-hydiOxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]c- arbonyl]butyl]amino]carbonyl]hexyl]-, [1S-[1R*,2R*,4R*(1R*,2R*)]]-; or DANS-Phe- His-LVA-Ile-Amp; L-Histidinamide. L-phenylalanyl-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4- [[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-, [1S- (1R*,2R*,4R*(1R*,2R*)]]- or H-Phe-His-LVA-Ile-Amp; L-Valinamide.L-phenylalanyl-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2- methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-, [1S- [1R*,2R*,4R*(1R*,2R*)]]-; or H-Phe-Val-LVA-Ile-Amp; L-Valinamide, L-valyl-N-[2-hydroxy-5-methyl- 1 -(2-methylpropyl)-4-[[[2-methyl- 1 - [[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]flS-[lR*,2R*,4R*(l- R*,2R*)]]-, diacetate (salt); or H-Val-Val-LVA-Ile-Amp; or L- Valinamide, N-acetyl-L-valyl-N-[2-hydroxy-5-methyl- 1 -(2-methylpropyl)-4-[[[2- methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyI]hexyl]-, [1S- [1R*,2R*,4R*(1R*,2R*)]]-, monoacetate (salt); or Ac-Val-Val-LVA-Ile-Amp. Nα-[(2S,4S,5S)-5-[[Nα[(S)-l-Acetoxy-l-benzyl)methylcarbonyl]-L-histidyl]- amino]-4-hydroxy-7-methyl-2-( 1 -methylethyl)- 1 -oxooctyl]-N- [2-pyridyl)ethyl]-L- isoleucinamide; or AcO-Phe-His-LVA-Ile-NH-(CH 2 ) 2 -pyridine. 4-Morpholinebutanamide,β-hydroxy-N-[2-[[2-hydroxy-5-methyl-l-(2-methylpro- pyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl- ]hexyl]am_uω]-l-(lH-imidazol-4-ylmethyl)-2-oxoethyl]-α-(l-naphthalenylmethyl)-τ-oxo-, [lS-[lR*[R*(αS*,βR*)],2R*,4R*(lR*,2R*)]]-; lH-Imidazole-4-propanamide, α-[[[5-(dimethylamino)-l-naphthalenyl]su- lfonyl]amino]-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinyl- m e t h y l ) a m i n o ) c arb o n y l ] b u t y l ] a m i n o ] c a rb o n y l ] h e x y l ] - , [ 1 S - [1R*(R*),2R*,4R*(1R*,2R*)]]-: or DANS-His-LVA-Ile-A p; lH-Imidazole-4-propanamide, c_-amino-N-[2-hydroxy-5-methyl- 1 -(2-methylpro- pyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-. [1S-[1R*(R*),2R*,4R*(1R*,2R*)]] or H-His-LVA-Ile-Amp; Octanamide, 5-[[2-(acetylam o)-3-memyl-l-oxobutyl]amino]-4-hydroxy-7-methyl- 2-(l-methylethyl)-N-[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]-, [2S- [N(lR*,2R*),2R*,4R*.5R*(R*)]]-_ monoacetate (salt); or Ac-Val-LVA-Ile-Amp; Ac- Asn-LV A-Ile-Amp ; Nα-[(2S,4S,5S)-5-[[(S)-(l-Hydroxy-l-benzyl)methylcarbonyl]amino]-4-hydroxy)- 7-methyl-2-(l -methylethyl)- 1 -oxooctyl]-N-(2-pyridinylmethyl)-L-isoleucinamide;or HO- Phe-LVA-Ile-Amp; lH-Imidazole-4-propanamide,N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2- methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-α-[(2- hydroxy-l-oxo-3-phenylpropyl)amino]-,[lS-[lR*[R*(R*)],2R*,4R*(lR* : ,2R*)]]-, 2- hydroxy-l,2,3-propanetricarboxylate(l 2) (salt) orphenyl-CH,-CH(OH)-C(O)-His-LVA- lie- Amp; L-α-Glutamine, N/u 2/d -[N-[[l, l-dimethylethoxy)carbonyl]-L-phenylalanyl]-N- [2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]- carbonyl]butyl]amino]rarbonyl]hexyl]-,[lS-[lR*,2R*4R*(lR*,2R*)]]-,monacetate(salt) or BOC-Phe-Glu-LVA-Ile-Amp; L-Histidinamide, N-[(l, l-dimethylethoxy)carbonyl]-3-(2-pyridinyl)alanyl-N-[2- hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbo- nyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]-orBOC-2-Py- L-.alpha.-Asparagine, N/u 2/d-[N-[(l, l-dimethyIethoxy)carbonyl]-L-phenylala- nyl]-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[2-methyl-l-[[(2-pyridinylme- thyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*,2R*,4R*(lR*,2R*)]]- ,monoacetate (salt) or BOC-Phe-Asp-LVA-Ile-Amp; L-.alpha.-Glutamine, N-[l, l-dimethylethoxy)carbonyl]-L-phenylalanyl-NO[l- (cyclohexylmethyl)-2-hydroxy-5-me_hyl-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carb- onyl]butyl]amino]carbonyl]hexyl]]-,[lS-[lR*,2R*,4R*(lR*.2R*)]]-, monoacetate (salt) or BOC-Phe-Glu-CVA-Ile-Amp; L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[3,3- difluoro-2-hydroxy-4-[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]-4- oxo-l-(phenylmethyl)butyl]- or CH 3 -C(O)-O-CH(benzyl)-C(O)-His-LVA-Ile-Amp; L-Glycyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R-isopropyl- hexanoyl-L-isoleucyl-2-pyridylmethylamide or Gly-His-CVA-Ile-Amp; L-Glycyl-L-hist_tdyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R-dihydroxy-hexanoyl- L-isoleucyl-2-pyridylmethylamide or Gly-His-CPD-Ile-Amp; 5-QuinolinylhydroxyacetyI-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Qoa(b)-His-CVA-Ile-Amp; Quinolinylhydroxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Qoa(a)-His-CVA-Ile-Amp; N tert-Butyloxycarbonyl-L-alanyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S-isopropyl- hexanoyl-L-isoleucyl-2-pyridylmethylamide or Boc-Ala-CVA-Ile-Amp; N-tert-Butyloxycarbonyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or BOC-His-CVA-Ile-Amp; Benzyloxycarbonyl-L-alanyl-L-alanyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or CBZ-Ala-Ala-CVA-Ile-Amp: L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[4-[[[2- [(2,6-diamino-4-pyrimidinyl)amino]ethyl]amino]carbonyl]-2-hydroxy-5-methyl-l-(2- methylpropyl)hexyl]-,[lS-(lR*,2R*,4R*)]- or BOC-Phe-ffis-LVA-(2,6-diaminc -pyrime- dinyl)amino-ethylamino ; Gly-CVD-Ile-Amp, and Gly-CPD-Ile-Amp; to prepare a medicament for inhibiting a retrovirus in a human cell infected with said retrovirus; and A compound of formula I wherein X is a) hydrogen, b) naphthyloxyacetyl, d) LVD, e) CPD, f) CLD, g) CcD, h) CCD, i) PPD, j) LID, k) LLd, or 1) LLD; wherein G 12 is a) absent, or b) He; wherein Z is a) Amp, b) Amp-NO, c) lysine, d) -NH-(CH 2 ) n -NH-pyridine, e) -NH-(CH 2 ) n -CH(OH)-phenyl, f) -NH-(CH 2 ) n -CH(OH)-C 1 -C 5 alkyl, or g) -NH-(CH 2 ) n -NH-(2,6-diamino-4-pyrimidinyl). wherein n is O to five, inclusive. By "amino acyl derivatives" is meant any of the naturally occurring amino acids such as: glycine, alanine, valine, leucine, isoleucine, phenylalanine, lysine, proline, tryptophan, methionine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, ornithine, and histidine, and synthetic derivatives thereof. These compounds may be in the L or D configuration and are well known and readily available to those skilled in the art. Susprisingly and unexpectedly, the compounds of the present invention are effective and potent inhibitors of HIV protease. The compounds of the present invention have also been found to inhibit HIV protease in cell cultures, as described below. Therefore, the compounds of formula I inhibit retroviral proteinases and thus inhibit the replication of the virus. They are useful for treating patients infected with human immunodeficiency virus (HTV) which results in acquired immunodeficiency syndrome (AIDS) and related diseases. The novel compounds of the present invention have low to moderate renin inhibitory activity but are surprisingly and unexpectedly potent retroviral protease inhibitors. The peptides of the present invention are also useful as novel human retroviral protease inhibitory peptide analogs. Therefore, the peptides of the present invention inhibit retroviral proteases and thus inhibit the replication of the vims. They are useful for treating human patients infected with a human retrovirus, such as human immunode¬ ficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and/or related diseases. The capsid and replicative enzymes (i.e. protease, reverse transcriptase, integrase) of retroviruses are translated from the viral gag and pol genes as polyproteins that are further processed by the viral protease (PR) to the mature proteins found in the viral capsid and necessary for viral functions and replication. If the PR is absent or nonfunctional, the virus cannot replicate. The retroviral PR, such as HIV-1 PR, has been found to be an aspartic protease with active site characteristics similar to those exhibited by the more complex aspartic protease, renin. The term human retrovirus (HRV) includes human immunodeficiency virus type I, human immunodeficiency virus type II, or strains thereof, as well as human T cell leukemia virus 1 and 2 (HTLV-1 and HTLV-2) or strains apparent to one skilled in the art, which belong to the same or related viral families and which create similar physiological effects in humans as various human retroviruses. Patients to be treated would be those individuals: 1) infected with one or more strains of a human retrovirus as determined by the presence of either measurable viral antibody or antigen in the serum and 2) in the case of HIV, having either a symptomatic AIDS defining infection such as i) disseminated histoplasmosis, ii) isopsoriasis, iii) bronchial and pulmonary candidiasis including pneumocystic pneumonia iv) non- Hodgkin's lymphoma or v) Kaposi's sarcoma and being less than sixty years old; or having an absolute CD4 lymphocyte count of less than 200/m 3 in the peripheral blood. Treatment would consist of maintaining an inhibitory level of the peptide used according to this invention in the patient at all times and would continue until the occurrence of a second symptomatic AIDS defining infection indicates alternate therapy is needed. More specifically, an example of one such human retrovirus is the human immunodeficiency virus (HIV, also known as HTLV-III or LAV) which has been recognized as the causative agent in human acquired immunodeficiency disease syndrome (AIDS), P. Duesberg, Proc. Natl. Acad. Sci. USA, 86:755 (1989). HIV contains a retro viral encoded protease, HIV-I protease, that cleaves the fusion polypeptides into the functional proteins of the mature virus particle, E.P. Lillehoj, et al., J. Virology, 62:3053 (1988); C. Debuck, et al., Proc. Natl. Acad. Sci., 84:8903 (1987). This enzyme, HIV-I protease, has been classified as an aspartyl protease and has a demonstrated homology to other aspartyl proteases such as renin, L.H. Pearl, et al., Nature 329:351 (1987); I. Katoh, et al.. Nature 329:654 (1987). Inhibition of HIV-I protease blocks the replication of HIV and thus is useful in the treatment of human AIDS, E.D. Clerq, J. Med. Chem. 29: 1561 (1986). Inhibitors of HIV-I protease are useful in the treatment of AIDS. Pepstatin A, a general inhibitor of aspartyl proteases, has been disclosed as an inhibitor of HIV-I protease, S. Seelmeier, et al, Proc. Natl. Acad. Sci. USA, 85:6612 (1986). Other substrate derived inhibitors containing reduced bond isosteres or statine at the scissle position have also been disclosed, M.L. Moore, et al., Biochem. Biophys, Res. Commun. 159:420 (1989); S. Billich, et al., 1. Biol. Chem. 263: 17905 (1988); Sandoz, D.E. 3812-576-A. Thus, the peptides of the present invention are useful for treating diseases caused by retroviruses, such as human acquired immunodeficiency disease syndrome (AIDS). The peptides of the present invention are also useful for treating non-human animals infected with a retrovirus, such as cats infected with feline leukemia virus. Other viruses that infect cats include, for example, feline infectious peritonitis virus, calicivirus, rabies virus, feline immunodeficiency virus, feline parvovirus (panleukopenia virus), and feline chlamydia. Exact dosages, forms and modes of administration of the peptides of the present invention to non-human animals would be apparent to one of ordinary skill in the art, such as a veterinarian. The compounds of formula I of the present invention are prepared as described in the publications listed in Table I below, all of which are incorporated by reference herein, or are prepared by methods analogous thereto, which are readily known and available to one of ordinary skill in the art of peptide synthesis. As is apparent to those of ordinary skill in the art, the compounds of the present invention can occur in several diastereomeric forms, depending on the configuration around the asymmetric carbon atoms. All such diastereomeric forms are included within the scope of the present invention. Preferably, the stereochemistry of the amino acids corresponds to that of the naturally occurring amino acids. The present invention provides for compounds of formula I or pharmacologi¬ cally acceptable salts and/or hydrates thereof. Pharmacologically acceptable salts refers to those salts which would be readily apparent to a manufacturing pharmaceutical chemist to be equivalent to the parent compound in properties such as formulation, stability, patient acceptance and bioavailablility. The compounds of the present invention are useful for treating patients infected with human immunodeficiency virus (HIV) which results in acquired immunodeficiency syndrome (AIDS) and related diseases. For this indication, the compounds of formula I are administered by oral, nasal, transdermal and parenteral (including i.m. and i.v.) routes in doses of 1 μg to 100 mg/kg of body weight. Those skilled in the art would know how to formulate the compounds of this invention into appropriate pharmaceutical dosage forms. Examples of the dosage forms include oral formulations, such as tablets or capsules, or parenteral formulations, such as sterile solutions. When the compounds in this invention are administered orally, an effective amount is from about 1 μg to 100 mg per kg per day. Either solid or fluid dosage forms can be prepared for oral administration. Solid compositions are prepared by mixing the compounds of this invention with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methyl cellulose, or functionally similar pharmaceutical diluents and carriers. Capsules are prepared by mixing the compounds of this invention with an inert pharmaceutical diluent and placing the mixture into an appropriately sized hard gelatin capsule. Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compounds of this invention with an acceptable inert oil such as vegetable oil or light liquid petrolatum. Syrups are prepared by dissolving the compounds of this invention in an aqueous vehicle and adding sugar, aromatic flavoring agents and preservatives. Elixirs are prepared using a hydroalcoholic vehicle such as ethanol, suitable sweeteners such as sugar or saccharin and an aromatic flavoring agent. Suspensions are prepared with an aqueous vehicle and a suspending agent such as acacia, tragacanth, or methyl cellulose. When the compounds of this invention are administered parenterally, they can be given by injection or by intravenous infusion. An effective amount is from about 1 μg to 100 mg per kg per day. Parenteral solutions are prepared by dissolving the compounds of this invention in water and filter sterilizing the solution before placing in a suitable sealable vial or ampule. Parenteral suspensions are prepared in substantially the same way except a sterile suspension vehicle is used and the compounds of this invention are sterilized with ethylene oxide or suitable gas before it is suspended in the vehicle. The exact route of administration, dose, or frequency of administration would be readily determined by those skill in the art and is dependant on the age, weight, general physical condition, or other clinical symptoms specific to the patient to be treated. Patients to be treated would be those individuals: 1) infected with one or more than one strain of a human immunodeficiency virus as determined by the presence of either measurable viral antibody or antigen in the serum and 2) having either a symptomatic AIDS defining infection such as i) disseminated histoplasmosis, ii) isopori- asis, iii) bronchial and pulmonary candidiasis including pneumocystis pneumonia, iv) non-Hodgkin's lymphoma, or v) Kaposi's sarcoma and being less than sixty years old; or having an absolute CD4 lymphocyte count of less than 200/mm 3 in the peripheral blood. Treatment would consist of maintaining an inhibitory level of the compounds o this invention in the patient at all times and would continue until the occurrence of a second symptomatic AIDS defining infection indicates alternate therapy is needed. The utility of representative compounds of the present invention has been demonstrated in several biological tests as described below. The HTV-1 protease has been expressed in E. coli, isolated, characterized an used to determine the inhibitory constants Q of potential inhibitory compounds a follows: The synthetic peptide H-Val-Ser-Gln-Asn-Tyr-Pro-He-Val-OH serves as th substrate for the measurement of HTV-1 protease activity. This peptide corresponds t the sequence from residue 128 to 135 in the HIV gag protein. Cleavage of the syntheti peptide, as well as the gag protein, takes place at the Tyr-Pro bond. HTV-1 proteas activity is measured at 30°C in 50 mM sodium acetate, pH 5.5, containing 10% glycerol, 5% ethylene glycol, 0.1 % Nonidet P-40 and 2.8 mM substrate in a total volume of 50 μl. After 30 minutes of incubation, 75 μl of 1 % trifluoroacetic acid (TFA) is added and the reaction mixture subjected to HPLC analysis. HPLC is carried out with a Vydac C I8 column (0.46 x 15 cm), eluting with a linear gradient of 0-30% acetonitrile over a period of 25 minutes at a flow rate of 1.0 ml/minute. The Kj values of representative compounds of formula I of the present invention are listed in Table II below. Several compounds of the present invention have been further evaluated for their ability to inhibit HIV replication in primary cultures of human peripheral blood lymphocytes. This assay is done by the following screening procedure. The following features characterize the primary screening: The screening tests are performed with primary human lymphocytes. Thereby, undesired testing of transformed cell lines is avoided in which host cell and virus may have undergone processes of mutual adaptation. Performance of cell culture in serum containing media closely mimics the in vivo situation. True antiviral effects of test compounds are readily distinguished from cytostatic/ cytotoxic reactions. By kinetic measurement of viral nucleic acids and proteins the viral replication is followed precisely. Testing in parallel on the level of nucleic acids (total HRV-RNA intra- and extracellular) and on the level of proteins (secreted p24) allows to differentiate the test compound's effects on virus replication and on the expression of viral proteins. This leads to additional information regarding the efficacy of the test compound. Tolerance of the cell culture against low amounts of organic solvents permits the investigation of hydrophobic substances also. The dose of the test compound causing half maximal suppression of virus replication is determined. The screening system is standardized and automated to a high degree. 1. TEST FOR TOXICITY Effects of the test compound on cell proliferation are determined by lymphocyte proliferation assays. Starting with a 100 micromolar solution, the test compound is 10 fold serially diluted. One tenth of the concentration of the test compound causing half maximal inhibition of cellular proliferation is employed for all subsequent testing. 2. IN VITRO INFECTION OF LYMPHOCYTES Peripheral human lymphocytes are isolated by density gradient centrifugation. After stimulation by mitogen the cells are infected with a standardized preparation of HRV. Subsequently, the infected cells are cultured in the presence of the test compound for four days. Individual cultures are established to measure viral replication two, three and four days following infection. Untreated cells and AZT-treated cells are included as controls in parallel with the test compounds under investigation. 2.1 DETECTION OF SECRETED VIRAL P24 The amount of viral core protein p24 synthesized and released by the infected cells is determined in the supernatant by capture-ELISA technique on days two, three and four. By comparing with a standard preparation, the amount of protein produced by the virus infected cells will be calibrated. 2.2 ASSAY FOR HIV-RNA The total amount of viral RNA synthesized by the infected lymphocytes is determined by a special nucleic acid hybridization technique on days two, three and four of culture. By including a standard preparation of HRV-RNA the amount of synthesized RNA will be quantified. In case a test compound shows antiviral effects in the primary screening, all steps of the primary screening will be repeated. In addition, viability of HRV-infected cells will be determined in parallel with assays for viral p24 and RNA. In order to evaluate the half maximal antiviral effectof the test compound, a concentration dependen- cy of the test compound action will be measured. The results of the testing of these compounds of the present invention in these assays is given in Table III below. Some of the compounds of the present invention have been further evaluated in a CV-1 cellular assay described below, where it was demonstrated that the retrovirus- inhibiting effect was due to the inhibition of HTV-1 protease. CV-1 cells were seeded at 2 x 10 "5 cells/well in 24 well Costar dishes and infected 6 to 12 hours later with vVK-1 at 5 PFU/cell (V. Karacostas, et al., "Human Immunodeficiency Virus-Like Particles Produced by a Vaccinia Virus Expression Vector (retrovirus/AIDS/virus assembly/reverse transcriptase, " Proc. Natl. Acad. Sci., USA, in press. 1989). The test compounds were dissolved in DMEM containing 2.5% fetal bovine serum and added to triplicate wells immediately after virus addition. Twenty- four hours after infection the culture medium was removed, the monolayer washed with 1 ml of PBS and the cells lysed by the addition of 0.1 ml of loading buffer (62.5 mM Tris-Hcl pH 6.8, 2.3 % SDS, 5 % B-mercaptoethanol, 10% glycerol). The cells lysates were collected individually, placed in boiling water for 3 minutes, and then 0.025 ml of each is subjected to electrophoresis on 12% SDS-polyacrylamide gels. The proteins were electroblotted onto nitrocellulose and analyzed by Western blotting. The primary antibodies were sheep anti-Pr24 and sheep anti-Prl7 and the secondary antibody in both cases was alkaline-phosphatase conjugated rabbit-anti sheep IgG (all obtained from Kirkegaard & Perry Laboratories, Gaithersburg, MD). Test compounds significantly inhibited proteolysis of the HIV-1 gag polyprotein (Pr55) to the mature viral structural proteins Pr24 and Prl7 in the above cells infected with the recombinant vaccina virus expressing the HIV-1 gag-pol genes. The HIV-1 like particles released from inhibitor-treated cells contained almost exclusively Pr55 and other gag precursors, but not Pr24. The following compounds of the present invention are preferred: l-Noa-His-ChaPSI[CHOHCHOH]Val-Ile-Amp; or lH-Imidazole-4-propanam- ide, N-[l-(cyclohexylmethyl)-2,3-dihydroxy-5-methyl-4-[[[2-methyl-l-[[(2-pyridinyl- methyl)amino]carbonyl]butyl]-[amino]carbonyl]hexyl]-o:-[[(l-naphthalenyloxy)acetyl]- amino]-, [1S-[1R*(R*),2S*,3S*,4S*(1R*,2R*)]]-; or NOA-His-CVD-Ile-Amp; Nα-[(2S,4S,5S)-5-[N-[Nα-(Phenoxymethylcarbonyl)-L-histidyl]amino-4- hydroxy-2-i « jcφropyl-7-methyl-l-oxooctyl]-N-[2-(2-pyridinylamino)ethyl]-L-isoleucinam- ide, acetic acid salt; or POA-His-LVA-Ile-NE^CH^NH-pyridine; or POA-His-LVA-He- lH-Imidazole-4-propanamide, N-[ 1 -(cyclohexylmethyl)-2-hydroxy-5-methyl-4- [[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-α [(phenoxyacetyl)amino]-, [1S-[1R*(R*),2R*,4R*(1R*,2R*)]]-; or POA-His-CVA-He- Amp; lH-Imidazole-4-propanamide^J-[l-(cycloheptylmethyl)-2-hydroxy-5-methyl-4- [[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-c- [(phenoxyacetyl)amino]-, [1S-[1R*(R*),2R*,4R*(1R*,2R*)]]-; or POA-His-chpVA-De- Amp; Cyclohexanehexanamide , δ-(acetylamino)-τ-hydroxy-α-( 1 -methylethyl)-N-[2- methyl-l-[[(pyridinylmethyl)amino]carbonyl]butyl], [αS-[N(lR*,2R ,,, ),αR*,τR*,δR*]]-; or Ac-CVA-Ile-Amp; Nα-[(2S, 4S, 5S)-5-[N-[Nc_-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide or NOA-His-CVA-Ile-Amp; Nc--[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl) (2-pyridinyl)alanyl]- amino]-6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L- isoleucinamide or NOA-His-CVA-Ile-Amp; Nα-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl- _ ' -oxohexyl]-N-[2-(2-pyridinylamino)ethyl]-L- isoleucinamide or NOA-His-CVA-πe-NH-(CH2)_-NH-(2-pyridine); Pentanoic acid, 5-[[l-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[2-methyl-l - [[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]amino]-4-[(lH-indol-2- ylcarbonyl)amino]-5-oxo-,[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]oilH-indol-2-yl-carbonyl- Glu-CVA-Ile-Amp; 2,5,11,14-Tetraazapentadecanoic acid, 7-hydroxy-3-(lH-imidazol-4-ylmethyl)-9- (l-methylethyl)-12-(l-methylpropyl)-6-(2-methylpropyl)-4, 10, 13-trioxo-15-(2-pyridinyl)- ,3-phenyl-2-propenyl ester, [3S-[1(E),3R*,6R*,7R*,9R*, 12R*(R*)]]- or phenyl- CH=CH-CH 2 -O-C(O)-His-LVA-Ile-Amp; Phenoxyacetyl-L-histidyl-5S-_mιinc^-cyclohexyl-3R,4R-dihydroxy-2R-isopropyl- hexanoyl-L-isoleucyl-2-pyridylmethylamide or POA-His-CVA-Ile-Amp; l-Naphtoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isobutyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-CLD-Ile-Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-2R-benzyl-3R,4R-dihydroxy-6-phenyl- hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-PPD-Ile-Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isopropyl-hexanoyl-L-isoleucyl-2-pyridinylamino-ethylamideorNOA-His-CVD-Ile-Apr; 5-Quinolinylhydroxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Qoa(b)-His-CV A-He-Amp ; l-Naphthoxyacetyl-L-histidyl-5S-amino-3R- R-dihydroxy-2R-isobutyl-7-methyl octanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-LLd-Ile-Amp; 2-Quinolinylcarbonyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R-isopropyl- hexanoyl-L-isoleucyl-2-pyridinylamino-ethylamide or Qc-Asn-CVD-Ile-Apr; Quinolinyl-2-carbonγl-L-asparaginyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or QC-Asn-CVA-Ile-Amp; L-Asparaginamide, l-(naphthoxy)acetyl-N-[2-hydroxy-5-methyl-l-(2-methyl- propyl)-4-[[[2-methyl-l-[[[2-(N-oxido)pyridinylmethyl]amino]carbonyl]butyl]amino]carb- onyl]hexyl]-N-alpha-methyl-, [1S-[1R*,2R*,4R*(1R*,2R*)]]- or NOA-Asp-CVA-Ile- Amp; L-Asparaginamide, [5-(t_riet_nyleneglycolmonomethylether)naphthoxy]acetyl-N- [2-hydroxy-5-methyl- 1 -(2-methylpropyl)-4-[[[2-methyl- 1 -[[[2-(N-oxido)pyridinylmethyl]- amino]c^rbonyl]butyl]amino]carbonyl]hexyl]-N-alpha-methyl{lS-[lR*,2R*,4R*(lR*,2- R*)]]- or 5-(triethyleneglycol monomethyl ether)-NOA-Asp-CVA-Ile-Amp; and L-Asparaginamide, [4-(-riethyleneglycolmonomethylether)naphthoxy]acetyl-N- [2-hydrOxy-5-me_hyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[[2-(N-oxido)pyridinylmethyl]- amino]carbonyl]butyl]amino]carbonyl]hexyl]-N-alpha-methyl{^S-[lR*,2R*,4R*(lR*,2- R*)]]- or 4-(triethyleneglycol monomethyl ether)-NOA-Asp-CVA-Ile-Amp. The following compounds of the present invention are most preferred: l-Noa-His-ChaPSI[CHOHCHOH]Val-Ile-Amp; or lH-Imidazole-4-propanam- ide, N-[ 1 -(cyclohexylmethyl)-2 , 3-dihydroxy-5-methyl-4-[[[2-methyl- 1 -[[(2-pyridinyl- methyl)amino]carbonyl]butyl]-[amino]carbonyl]hexyl]-c--[[(l-naphthalenyloxy)acetyl]- amino]-, [1S-[1R*(R*),2S*,3S*,4S*(1R*,2R*)]]-; or NOA-His-CVD-Ile-Amp; Quinolinyl-2-carbonyl-L-asparaginyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or QC-Asn-CVA-Ile-Amp; L-Asparaginamide, [5-(triethyleneglycol monomethyl ether)naphthoxy]acetyl-N-[2- L-Asparaginamide, [5-(triethyleneglycolmonomethylether)naphthoxy]acetyl-N- [2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[[2-(N-oxido)pyridinyl- methyl]amino]carbonyl]butyl]amino]carbonyl]hexyl]-N-alpha-methyl- , [ lS-[ IR* ,2R*, - 4R*(1R*,2R*)]]- or 5-(triethyleneglycol monomethyl ether)-NOA-Asp-CVA-Ile-Amp. L-Asparaginamide ether)naphthoxy]acetyl-N-[2-hydroxy-5-methyl-l-(2- memylpropyl)-4-[[[2-m_^yl-l-[[( -(N-oxido)pyridinylmethyl]amino]carbonyl]butyl]amin- o]carbonyl]hexyl]-N-alpha-methyl-, [1S-[1R*,2R*,4R*(1R*,2R*)]]- or 4-(triethylenegl- ycol monomethyl ether)-NOA-Asp-CVA-Ile-Amp; Nα-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl) (2-pyridinyl)alanyl]- amino]-6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L- isoleucinamide or NOA-His-CVA-Ile-Amp; Nα-[(2S, 4S. 5S)-5-[N-[Nc_-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl- l-oxohexyl]-N-[2-(2-pyridinylamino)ethyl]-L- isoleucinamide or NOA-His-CVA-Ile-NH-(CH 2 ) 2 -NH-(2-pyridine); 2-Quinolinylcarbonyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R-isopropyl- hexanoyl-L-isoleucyl-2-pyridinylamino-ethylamide or Qc-Asn-CVD-Ile-Apr; and l-Naphthoxyacetyl-L-histidyl-5S-amino-2R-benzyl-3R,4R-dihydroxy-6-phenyl- hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-PPD-Ile-Amp. DESCRIPTION OF THE PREFERRED EMBODIMENTS In the Preparations and Examples below and throughout this document: 'H-NMR is nuclear magnetic resonance; Ac is acetyl; Aco is acetyloxy; Amp is 2-(aminomethyl) pyridine; Amp-NO is (2-pyridylmethyl) amino, pyridine N-oxide; Apr is 2-pyridinylamino-ethylamide. . - Asn is asparagine; Boc is t-butoxycarbonyl; BOP is benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophos phate; Bz is benzyl; C is centigrade; Cbz is benzyloxycarbonyl; CcD is the moiety of formula X wherein R, is cyclohexyl, R 2 is α-hydroxy, _ is α-hydroxy and R 3 is /S-CH 2 -cyclohexyl; CCD is the moiety of formula X wherein R, is cyclohexyl, R 2 is α-hydroxy R 3 is α-CH 2 -cyclohexyl and R, is α-hydroxy; CDC1 3 is deuteriochloroform; Celite is a filter aid; CVA is Cha*[CH(OH)CHJVal of formula X wherein R, is cyclohexyl, R 2 i hydrogen, R 3 is α-isopropyl and R < is α-hydroxy; chpVA is the moiety of formula X wherein R, is cycloheptyl, R 2 is hydroge and R 3 is α-isopropyl, and R, is α-hydroxy; CLA is the moiety of formula X wherein R, is cyclohexyl, R 2 is hydrogen, R 3 is -α-isobutyl, and R, is α-hydroxy; CLD is the moiety of formula X wherein R, is cyclohexyl, R 2 is α-hydroxy, R, is α-hydroxy and R 3 is α-isobutyl; CPD is the moiety of formula X wherein Rj is cyclohexyl, R 2 is α-hydroxy, R, is α-hydroxy and R 3 is α-benzyl; CVD is the moiety of formula X wherein R, is cyclohexyl, R 2 is α-hydroxy, R 3 is α-isopropyl and is α-hydroxy; CVD' is the moiety of formula X wherein R t is cyclohexyl, R 2 is 0-hydroxy, R, is α-hydroxy, and R 3 is α-isopropyl; DANS is dansyl or 5-dimethylaminonaphthalenesulfonyl; DCC is dicyclohexylcarbodiimide; DEPC is diethylphosphoryl cyanide; EtOAc is ethyl acetate; g is grams; τ-Glu is τ-glutamic acid; Gly is glycine; His is histidine; N-MeHis is Nα-methyl histidine; HOBT is 1-hydroxybenzotriazole; HPLC is high performance liquid chromatography; He is isoleucine; IR is infrared spectra; IVA is isovaleryl; LCA is the moiety of formula X wherein R, is isopropyl, R 2 is hydrogen, R 3 is -α-CH 2 -cyclohexyl and R < is α-hydroxy; LFA is the difluoro version of LVA as described more fully in PCT Pub. No. WO86/06379 (6 November 1985), and is the moiety of formula IV wherein R, is isopropyl; LLA is the moiety of formula X wherein R, is isopropyl, R 2 is hydrogen, R 3 is -α-isobutyl, and R 4 is α-hydroxy; LID is the moiety of formula X wherein R, is isopropyl, R 2 is 3-hydroxy, j s 3-hydroxy and R 3 is .-isobutyl; LLd is the moiety of formula X wherein R t is isopropyl, R is α-hydroxy, R, s α-hydroxy, and R 3 is /S-isobutyl; LLD is the moiety of formula X wherein R, is isopropyl, R 2 is α-hydroxy, R, is α-hydroxy, and R 3 is α-isobutyl; LPA is the moiety of formula X wherein R ! is isopropyl, R 3 is hydrogen, R 3 is -α-benzyl and R, is α-hydroxy; LVA is LeuΫ(CH(0H)CH 2 )Val with the S configuration at C4 (the hydroxyl- bearing carbon atom) of the formula X wherein R ! is isopropyl, R 2 is hydrogen, R 3 is α-isopropyl and R, is α-hydroxy; LVD is the diol version of LVA as described more fully in PCT Pub. No. WO87/05302 (11 September 1987) and is the moiety of formula X wherein R[ is isopropyl, R 2 is α-hydroxy, < is α-hydroxy and R 3 is α-isopropyl; LVDA' is the moiety of formula X wherein R, is isopropyl, R 2 is S-hydroxy, R, is α-hydroxy, and R 3 is α-isopropyl; M or mol is mole; Mba is 2S-methylbutylamine; Me is methyl; ml is milliliter; MPLC is medium pressure liquid chromatography; MS is mass spectroscopy; NOA is (l-naphthyloxy)acetyl; Ph is phenyl; Phe is phenylalanine; POA is phenyloxyacetyl; PPD is the moiety of formula X wherein Rj is phenyl, R 2 is α-hydroxy, R, i α-hydroxy and R 3 is α-benzyl; Pro is proline; 2-Py-Ala is D,L-2-pyridyl-alamine. RIP means a compound having the formula H-Pro-His-Phe-His-Phe-Phe-Va Tyr-Lys-0H.2(CH 3 C(0)0H).XH 2 0 which is a known renin-inhibiting peptide; TBA is t-butylacetyl; TBAP is tetra-n-butylammonium phosphate; TEA is triethylamine; TFA is trifluoroacetic acid; THF is tetrahydrofuran; TLC is thin layer chromatography; Tos is p-toluenesulfonyl: TsOH is p-toluenesulfonic acid; Tyr is tyrosine; (OCH 3 )Tyr is O-methyl tyrosine; and Val is valine. In formula X, wherein the variables are as defined above, "α" is used to indicate the substituent is below the plane of the drawing and "β" is used to indicate the substituent is above the plane of the drawing. The wedge-shape line indicates a bond which extends above the plane of the paper relative to the plane of the compound thereon. The dotted line indicates a bond which extends below the plane of the paper relative to the plane of the compound thereon. The following Preparations and Examples illustrate the present invention: Examples 1 - 103. Using the chemical procedures, starting materials, and reactants described in the publications listed in Table I below, which are incorporated by reference herein, or methods analogous thereto, all of which are readily known and available to one of ordinary skill in the art, the following compounds of the present invention, having the indicated physical characteristics, are prepared: (1) L-Isoleucinamide, N 2 -(5-_uιιino-4-hydroxy-2-(l-me_hylethyl)-l-oxooctyl]- N-(2-pyridinylmethyl)-, trifluoroacetate, (S,S,S)-; or H-LVA-He-Amp; (2) lH-Imidazole-4-propanamide, N-[2-hydroxy-5-methyl-l-(2-methylpr- opyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]- α-[(phenoxyacetyl)-amino]-, [1S-[1R*,2R*,4R*(1R*,2R*)]]- ; POA-His-LVA-He-Amp; (3) lH-Imidazole-4-propanamide, N-[l-(cyclohexylmethyl)-3,3-difluoro-4- [[2-methyI-l-[[(2-pyridinylmethyl)___ ino]carbonyl]butyl]amino]-2,4-dioxobutyl]-α-[[(l- naphthalenyloxy)acetyl]amino]-, [lS-(lR*(αR*),2R*]]-; or NOA-His-LFA-Ile-Amp; (4) lH-Imidazole-4-propanamide, α-[[2-(acetyloxy)-3-(l-naphthalenyl)-l- oxopropyl]amino]-N-[l-(cyclohexylmethyl)-3,3-difluoro-4-[[2-methyl-l-[[(2-pyridinyl- methyl)amino]carbonyl]butyl]amino]-2,4-dioxobutyl]-, [!S-[lR*[αR*(R*)],2R*]]-; (5) L-Histidinamide, N-[( 1 , 1 -dimethylethoxy)cart>onyl]-L-phenylalanyl-N-[l - (cyclohexylmethyl)-3,3-difluoro-4-[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]- butyl]amino]-2,4-dioxobutyl]-; or Boc-Phe-His-LFA-Ile-Amp: (6) lH-Imidazole-4-propanamide, N-[l-(cyclohexylmethyl)-2-hydroxy-6- methyl-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]- heptyl]-α-[(phenoxyacetyl)amino]-, [1S-[1R*(R*),2R*,4S*(1R*,2R*)J]-; or POA-His- CLA-Ile-Amp; (7) lH-Imidazole-4-propanamide, N-[2,3-dihydroxy-5-methyl-l-(2- methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]- carbonyl]hexyl]-α-[(phenoxyacetyl)amino]-[lS-[lR*(R*),2S*,3R*,4R*(lR*,2R*)]]-;or POA-His-LVDA-Ile-Amp; (8) lH-Imidazole-4-propanamide?--[2,3-dihydroxy-5-methyl-4-[[(2-methyl- butyl)amino]carbonyl]-l-(2-methylpropyl)hexyl3-α-[(phenoxyacetyl)amino]-, [1R- [1R*(S*),2S*,3S*,4S*(S*)]]-; or POA-His-LVDA-Mba; (9) Boc-Phe-His-Cha ρsi[CHOHCHOH]Val-He-Amp; or L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[l-(cyclohexylmethyl)-2,3- dihydroxy-5-methyl-4-[[[2-methyl-l-[[(2-pyridinylmethyl)_mino]carbonyl]butyl]amino]- carbonyl]hexyl]-, [lS-[lR*,2S*,3S*,4S*(lR 1,t ,2R*)]]-;or BOC-Phe-His-CVD-Ile-Amp; (10) 1-Noa-His-Cha PSI[CHOHCHOH]Val-Ile-Amp; or lH-Imidazole-4- propanamide , N-[ 1 -(cyclohexylmethyl)-2 , 3-dihydroxy-5-methyl-4-[[[2-methyl- 1 -[[(2- pyridinylme yl)amino]carbonyl]butyl]-[amino]carbonyl]hexyl]-α-[[(l-naphthalenyloxy)- acetyljamino]-, [1S-[1R*(R*),2S*,3S*,4S*(1R*,2R*)]]-; or NOA-His-CVD-Ile-Amp; (11) lH-Imidazole-4-propanamide, N-[2-hydroxy-6-methyl-l-(2-methyl- p-Opyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]c-_rbonyl]butyl]amino]carbonyI]hep- tyl]-α-[(phenoxyacetyl)amino]-, [lS-[lR ,,t (R*),2R*,4S*(lR*,2R*)]]-; or POA-His-LLA- Ile-Amp; (12) lH-Imidazole-4-propanamide, N-[2-hydroxy-l-(2-methylpropyl)-5-[[2- methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]-5-oxo-4-(phenylmethyl)- pentyl]-α-[(phenoxyacetyl)amino]-, [1S-[1R*(R*),2R*,4S*,5(1R*,2R*)]]-; or POA-His- LPA-He-Amp; (13) lH-Imidazole-4-propanamide^-[4-(cyclohexylmethyl)-2-hydroxy-l-(2- methylpropyl)-5-[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]-5 oxopentyl]-α-[(phenoxyacetyI)amino]-, [1S-[1R*(R*),2R*,4S*,5(1R*,2R*)]]-; or POA- His-LCA-Ile-Amp; (14) L-Histidinamide, N-[(l,l-dimethylethoxy)caιbonyl]-L-phenylalanyl-N-[2- hydroxy-l-(2-methylpropyl)-5-[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]- amino-5-oxo-4-(phenylmethyl)pentyl]-, [1S-[1R*,2R*,4S*,5(1R*,2R*)]]-; or Boc-Phe- His-LPA-Ile-Amp; (15) L-Histidinamide, N-[(l,l-dimeώylethoxy)ca_ )onyl]-L-phenylalanyl-N-[4- (cyclohexylmethyl)-2-hydroxy- 1 -(2-methylpropyl)-5-[[2-methyl- 1 -[[(2-pyridinylmethyl)- amino]carbonyl]butyl]amino]-5-oxopentyl]-, [1S-[1R*,2R*,4S*,5(1R*,2R*)]]-; or Boc- Phe-His-LCA-Ile-Amp; (16) L-Talonamide, 6-cyclohexyl-2,5,6-trideoxy-5-[N-[N-[(l,l-dimethyleth- oxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-2-(l-methylethyl)-N-[2-methyl-l-[[(2- pyridinylmethyl)amino]carbonyl]butyl]-, [S-(R*,R*)]-; or Boc-Phe-His-CVD'-Ile-Amp; (17) L-Histidinamide, N-[(l,l-dimethylethoxy)carbonyl]-L-phenylalanyl-N- (2,3-dihydroxy-5-methyl-l-(2-methylpropyl)-4-[[(2-methyl-l-[[(2-pyridinylmethyl)- amino]carbonyl]butyl]amino]carbonyl]hexyl]-, [lS-[lR*,2S*,3R*,4-Amp; or Boc-Phe- His-LVDA'-Ile-Amp; FAB-MS: [m + H] + at 835.5084; (18) 4-Morpholinebutanamide, β-hydroxy-N-[2-[[2-hydroxy-5-methyl-l-(2- methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]- carbonyl]hexyl]amino]-l-(lH-imidazol-4-y_methyl)-2-oxoethyl]-α-(l-naphthalenylmethyl)- T-oxo-, [lS-[lR*p-*(αS*,βR*)],2R*,4R*(lR*,2R*)]]-; (19) lH-Imidazole-4-propanamide, N-[l-(cyclohexylmethyl)-2-hydroxy-5- methyl-4-[[[2-memyl-l-[[(2-pyridinyImethyl)am o]c -- uix)nyl]butyl]ammo]car >nyl]hexyl]- α-[(phenoxyacetyl)amino]-, [1S-[1R*(R*),2R*,4R*(1R*,2R*)]]-; or POA-His-CVA-He- Amp; FAB-MS: [m + H] + at 746.4598; (20) lH-Imidazole-4-propanamide, α-[[[5-(dimethylamino)-l-naphthalenyl]su- lfonyl]amino]-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2- pyridinylmethyl)amino]carbonyl] utyl]amino]carbonyl]hexyl]-, [1S-[1R*(R*),2R*,- 4R*(1R*,2R*)]]-; or DANS-His-LVA-He-Amp; (21) lH-Imidazole-4-propanamide, N-[l-(cycloheptylmethyl)-2-hydroxy-5- methyl-4-[[[2-memyl-l-[[(2-pyridinylmethyl)aιm^o]caιt)onyl]butyl]-Ui__no]ca__ rø α-[(phenoxyacetyl)amino]-,[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-;oιPOA-His-chpVA-Ile- Amp; (22) L-Histidinamide, N-[[5-(dimethylamino)-l-naphthalenyl]sulfonyl]-L- phenylalanyl-N-[2-hydroxy-5-methyl- l-(2-methylpropyl)-4-[[[2-methyl-l -[[(2- pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-[lS-[lR*,2R' ,c ,4R*(lR*,- 2R*)]]-; or DANS-Phe-His-LVA-Ile-Amp; (23) Octanamide5-[(3,3-dimethyl-l-oxobutyl)amino]-4-hydroxy-7-methyl-2- (l-methylethyl)-N-[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]-, [2S- [1(1R*,2R*),2R*,4R*,5R*]]- OΓ TBA-LVA-He-Amp; FAB-MS: [m + H) + at 533; (24) Cyclohexanehexanamide, δ-[(3,3-dimethyl-l-oxobutyl)amino]-τ-hydroxy- α-(l-methylethyl)-N-[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]-, [αS- [N(lR*,2R*),αR*,τR*,δR*]]- or TBA-CVA-Ile-Amp; FAB-MS: [m -I- H] + at 573; (25) lH-Imidazole-4-propanamide, α-amino-N-[2-hydroxy-5-methyl-l-(2- methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]- carbonyljhexyl]-, [1S-[1R*(R*),2R*,4R*(1R*,2R*)TJ or H-His-LVA-Ile-Amp; (26) L-Histidinamide, L-phenylalanyl-N-[2-hydroxy-5-methyl-l-(2-methylpro- pyl)-4-[[[2-memyl-l-[[(2-pyridinylmethyl)amino]c_jbonyl]butyl]amino]carbonyl]hexyl]-, [1S-(1R*,2R*,4R*(1R*,2R*)]]- or H-Phe-His-LVA-Ile-Amp; (27) Cyclohexanehexanamide, δ-amino-τ-hydroxy-α-(l-methylethyl)-N-[[2- methyl- 1 -[[(2-pyridinylmethyl)]amino]carbonyl]butyl]- dihydrochloride,[αS-[N( 1 R* , 2R- *),αR*,τR*,δR*]]- or H-CVA-Ile-Amp; FAB-MS: [m + H] + at 475; (28) Cyclohexanehexanamide, δ-(acetylamino)-τ-hydroxy-α-(l-methylethyl)- N-[2-methyl-l-[[(pyridinylmethyl)amino]carbonyl]butyl], [αS-[N(lR*,2R*),αR*,rR*,- δR*]]-; or Ac-CVA-He-Amp; FAB-MS: [m + H] + at 517; (29) Octanamide, 5-(acetylamino)-4-hydroxy-7-methyl-2-(l-methylethyl)-N-[2- methyl-l-[[(2-pyridinylmemyl)a_r_ino)carbonyl]butyl]-, [2S-[N(1R*,2R*),2R*,4R*,5R*]]-, monoacetate (salt); or Ac-LVA-He-Amp; FAB-MS: [m + H] + at 477; (30) L-Valinamide, L-phenylalanyl-N-[2-hydroxy-5-methyl-l-(2-methylpropy l)- 4 -[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]_mino]c__rbonyl]hexyl3- [1S-[1R*,2R*,4R*(1R*,2R*)]]-; or H-Phe-Val-LVA-Ile-Amp; (31) Octanamide, 5-[[2-(ace-ylammo)-3-methyl-l-oxobutyl]amino]-4-hydroxy 7-methyl-2-(l-methylethyl)-N-[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]- [2S-[N(1R*,2R*),2R*,4R*,5R*(R*)]]-, monoacetate (salt); or Ac-Val-LVA-Ile-Amp; FAB-MS: [m + H] + at 576; (32) L-Valinamide, L-valyl-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[H2 methyl-l-[[(2-pyridinylmethyl)amino]carbonyI]butyl]amino]carbonyl]hexyl]-, [1S- [1R*,2R*,4R*(1R*,2R*)]]-, diacetate (salt); or H-Val-Val-LVA-IIe-Amp; FAB-MS: [m + H] + at 633; (33) Ac-Asn-LVA-Ile-Amp; FAB-MS: [ + H] + at 591; (34) L-Valinamide, N-acetyl-L-valyl-N-[2-hydroxy-5-methyl-l-(2-methylprop- yl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-, " [1S-[1R*,2R*,4R*(1R*,2R*)]]-, monoacetate (salt); or Ac-Val-Val-LVA-Ile-Amp; FAB¬ MS: [m + H] + at 675; (35) Nα-[(2S,4S,5S)-5-[N-[Nα-(Phenoxymethylcarbonyl)-L-histidyl]amino-4- hydroxy-2-isopropyl-7-methyl-l-oxooctyl]-N-[2-(2-pyridinylamino)ethyl]-L-isoleucin- amide, acetic acid salt; or POA-His-LVA-Ile- TH^H^NH-pyridine; FAB-MS: [m + H] + at 735; (36) IVA-LVA-He-Amp; FAB-MS: [m + H] + at 519; (37) N-[(2S ,4S ,5S)-5-[Nα-[Nα-(tert-Butoxycarbonyl)-O-methyl-L-tyrosyl]-L- histidyl]amino]-4-hydroxy-7-methyl-2-phenylmethyl-l-oxooctyl]-N-[(S)-2-hydroxy- propyljamine; or Boc-OMeTyr-His-LPA-NH-CH 2 -CH(CH 3 )(OH); FAB-MS: [m + H] + at 751; (38) Nα-[(2S ,4S ,5S)-5-|^-[Nα-(Phenoxyme-hylcarbonyl)-L-histidyl]amino]^- hydroxy-2-isopropyI-7-methyl-l-oxooctyl]-N-(2,3-dihydroxypropyl)-L-isoleucinamide; or POA-His-LVA-Ile-NH-CH,-CH(OH)-CH 2 OH; FAB-MS: [m + H] + at 689; (39) Nα-[(2S ,4S ,5S)-5-|^-[Nα-(Phenoxymemylcarbonyl)-L-histidyl]-amino^. - hydroxy-2-isopropyl-7-methyl-l-oxooctyl]-N-(2-hydroxypropyl)-L-isoleucinamide; or POA-His-LVA-Ile-NH-CH 2 -CH(CH 3 )(OH); FAB-MS: [m + H] + at 673; (40) Nα-[(2S,4S,5S)-5-[[Nα[(S)-l-Acetoxy-l-benzyl)methylcarbonyl]-L- histidyl]arnmo]-4-hydroxy-7-methyl-2-(l-methylethyl)-l-oxooctyl]-N-[2-pyridyl)ethyl]-L- isoleucinamide; or AcO-Phe-His-LVA-He-NH-(CH 2 ) 2 -pyridine; FAB-MS: [m + H] + at 776; (41) Nα-[(2S,4S,5S)-5-[[(S)-(l-Hydroxy-l-benzyl)meti lcarbonyyamino]^ hydroxy)-7-methyl-2-( 1 -methylethyl)- 1 -oxooctyl]-N-(2-pyridinylmethyl)-L-isoleucinamide; or HO-Phe-LVA-Ile-Amp; High Resolution MS: 583.3880; (42) Nα-[(2S, 4S, 5S)-5-| -psrα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]- 6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-i-»leucmamide, pyridine N-oxide or NOA-His-CVA-He-Amp-NO. HR FAB MS [m+H] + at m/z 812.4748; (43) Nα-[(2S, 4S, 5S)-5-[N-[Nα-(P-toluenesulfonyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide or p-Tolunesulfonyl-His-CVA-Ile-Amp. HR FAB MS [m + H] + at m/z 766.4348; (44) Nα-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]- 6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide or NOA-His-CVA-Ile-Amp. HR FAB MS [m + H] + at m/z 796.4794; (45) Nα-[(2S , 4S , 5S)-5-[N-[Nα-(Phenoxymethylcarbonyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide, pyridine N-oxide or POA-His-CVA-He-Amp-NO. HR FAB MS [m -I- H] + at m/z 762.4574; (46) Nα-[(2S, 4S, 5S)-5-[N-[Nα-(p-Toluenesulfonyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide, pyridine N-oxide or p-Toluenesulfonyl-His-CVA-Ile-Amp-NO. HR FAB MS [m + H] + at m/z 782.4238; (47)Ne-[(2S,4S,5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl- 1 -oxohexyl]-L-lysine, trifluoroacecticacid salt or NOA- His-CVA-L-lysine,trifluoroacetic acid salt. HR FAB MS [m + H] + at m/z 721.4309; (48) N-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl- 1 -oxohexyl]-N-[2-(2-pyridinylamino]ethyl]-amine or NOA-His-CVA-NH-(CH 2 ) 2 -NH-(2-pyridine) HR FAB MS [m + H] + at m/z 712.4195; (49) N-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-[2-(2-pyridinylamino)]ethyl]amine,- pyridine N-oxide or NOA-His-CVA-NH(CH 2 ) 2 -NH-(2-pyridine). HR FAB MS [m + H] + at m/z 728.4144; (50) Nα-[(2S , 4S , 5S)-5-[N-[Nα-( 1 -Naphthalenyloxyacetyl)(2-pyridinyl)alanyl]- amino]-6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L isoleucinamide or NOA-His-CVA-He-Amp. HR FAB MS [m + H] + at m/z 807.4795; (51) Nα-[(2S, 4S, 5S)-5-[N-[Nα-[(3-Pyridinyl)-methylcarbonyl]-L-histidyl] amino]-6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L isoleucinamide or (3-pyridinyl)-methyl-carbonyl-His-CVA-Ile-Amp. HR FAB MS [ + H] + at m/z 731.4625; (52) Ne-[Nα-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl] amino]-6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-L-isoleuncyI]-L-lysine, trifluoroacetic acid salt or NOA-His-CVA-Ile-L-lysine, trifluoroacetic acid salt. HR FAB MS [m-f-H] + at m/z 834.5151; (53)Nα-[(2S ,4S ,5S)-5-[N- Nα-(l -NaphthalenyloxyacetyI)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-[2-(2-pyridinylamino)ethyl]-L- isoleucinamide or NOA-His-CVA-Ile-NH^CH^-NH-^-pyridine). HR FAB MS [m+H] + at m/z 825.5040; (54) lH-Imida∞le-4-pror_βn___nide,N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4- [[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-α-[(2- hydroxy-l-oxo-3-phenylpropyl)amino]-,[lS-[lR*[R*(R*)],2R*,4R*(lR*,2R*)]]-, 2- hydroxy-l,2,3-propanetricarboxylate (12) (salt) orphenyl-CH 2 -CH(OH)-C(O)-His-LVA- Ile-Amp. HR FAB MS [m +H] + : 720.4456; (55) lH-Imidazole-4-propanamide,N-[2-hydroxy-4-[[[l-[[(2-hydroxy-2-phαιylet- hyl)amino]carbonyl]-2-memylbutyl]amino]caιbonyl]-5-methyl-l-(2-methylpropyl)hexyl]-α- [(phenoxyacetyl)amino]-, monoacetate (salt) or POA-His-LVA-Ile-NH-CH 2 -CH(OH)- phenyl. HR FAB MS [m +H] + : 735.4444; (56) L-α-Glutamine, N/u 2/d -[N-[[l,l-dimethylethoxy)carbonyl]-L-phenylal- anyl]-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinyl- methyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*,2R*4R*(lR*,2R*)]]- ,monacetate (salt) or BOC-Phe-Glu-LVA-Ile-Amp. HR FAB MS [m +H] + : 811.4988; (57) Pentanoic acid, 5-[[l-(cyclohexylmethyl)-2-hydroxy-4-[[(2-hydroxy- propyl)amino]carbonyl]-5-methylhexyl]amino]-5-oxo-4-[(phenoxyacetyl)amino]-orPOA- Glu-CVA-NH-CH 2 CH(CH 3 )(OH). HR FAB MS [m +H] + : 630.3146; (58) lH-Imidazole-4-propanamide, N-[l-(cyclohexylmethyl)-2-hydroxy-4-[[(2- hydroxypropyl)amino]carbonyl]-5-methylhexyl]α-[(phenoxyacetyl)amino]- , monoacetate (salt) or POA-His-CVA-NH-CH 2 -CH(OH)(CH 3 ). HR FAB MS [m +H] + : 600.3770; (59) Pentanoic acid, 5-[[l-(cyclohexylmethyl)-2-hydroxy-5-methyl- -[[[2-methyl- l-[[(2 yridinylmethyl)amino]caιt )nyl]butyl]amino]carbonyl]hexyl]amino]-4-[(lH-indol- 2-ylcarbonyl)amino]-5-oxo-,[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]- or lH-indol-2-yl- carbonyl-Glu-CVA-Ile-Amp. HR FAB MS [m +H] + : 747.4437; (60)L-.alpha.-Glutamine, N-[l-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[2- memyl-l-[[(2-pyridinylmethyl)amino]ca_τjonyl]butyl]amino]carbonyl]hexyl]-N/u 2/d-L- phenylalanyl-, [1S-[1R*,2R*,4R*(1R*,2R*)]]-, bis(trifluoracetate) (salt) or Phe-Glu- CVA-Ile-Amp. HR FAB MS [m +H] + : 751.4756; (61^-PyridineacetamideJ^-[2-[[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2- methyl- 1 -[[(2-pyridinylmethyr)amino]caιτx)nyl]butyl]-_mino]carbonyl]hexyl]amino]- 1 -( 1H- imidazol-4-ylmethyl)-2-oxoethyl]-[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]- r (2-Pyridyl)acetyl- His-LVA-Ile-Amp; (62) 4-Pyridineacetamide, N-[2-[[2-hydroxy-5-me_hyl-l-(2-methylpropyl)-4- [[[2methyl- l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]amino]- 1 - (lH-imidazol-4-ylmethyl)-2-oxoethyl]-[lS-[lR*(R*),2R 1, ',4R ,,, (lR*,2R*)]]-or (4- Pyridyl)acetyl-His-LVA-Ile-Amp; (63) L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-3-(2-pyridinyl)alanyl- N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]c- arbonyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]-orBOC-2- Py-Ala-His-LVA-Ile-Amp. HR FAB MS [m +H] + : 820.5112; (64) L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[4- [[[2-[(2,6-diamino-4-pyrimidinyl)amino]e-hyl]amino]carbonyl]-2-hydroxy-5-methyl-l-(2- methylpropyl)hexyl]-,[lS-(lR*,2R*,4R*)]- or BOC-Phe-His-LVA-(2,6-diamino-4-pyrime- dinyl)amino-ethylamino. HR FAB MS [m + H] + : 766.4727; (65) L-.alpha.-Asparagine, N/u 2/d-[N-[(l,l-dimethylethoxy)carbonyl]-L- phenylalanyl]-N-[2-hydroxy-5-me-hyl-l-(2-methylpropyl)-4-[[2-methyl-l-[[(2-pyridinylme- thyl)amino]carbonyl]butyl]amino]carbonyl]hexyI]-,[lS-[lR*,2R ,,, ,4R*(lR*,2R*)]]- , monoacetate (salt) or BOC-Phe-Asp-LVA-Ile-Amp. HR FAB MS [m +H] + : 797.4857; (66) lH-Indole-2-carboxamide, N-[2-([2-hydroxy-5-methyl- 1 -(2-methylpropyl)- 4-[[2-methyl- 1 -[[(2-pyridinylmethyl)amino]carbonyl]butyl]carbonyl]hexyl]amino]- 1 -( 1H- imidazol-4-ylmethyl)-2-oxoethyl]-,[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-or N-(Indolyl-2- carbonyl)-His-LVA-Ile-Amp; (67) L-.alpha.-Glutamine, N-[l,l-dimethylethoxy)carbonyl]-L-phenylalanyl- N0[l-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amin- o]caιtjonyl]butyl]amino]carbonyl]hexyl]]-,[lS-riR*,2R*,4R*(lR*,2R*)]]-, monoacetate (salt) or BOC-Phe-Glu-CVA-Ile-Amp. HR FAB MS [m + H] + : 851.5297; (68) 2,5,11,14-Tetraazapentadecanoic acid, 7-hydroxy-3-(lH-imidazol-4- ylmemyl)-9-(l-me ylethyl)-12-(l-methylpropyl)-6-(2-methylpropyl)-4,10,13-trioxo-15-(2- pyridinyl)-,4-pyridinylmethyl ester, [3S-[3R*,6R*,7R*,9R*, 12R*(R*)]]- or Ioc-His- LVA-He-Amp; (69)L-Histidinamide.N-[( 1 , 1 -dimethylethoxy)carbonyl]-L-phenylalanyl-N-[3 , 3- difluoro-2-hydroxy-4-[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]-4- oxo-l-(phenylmethyl)butyl]- or CH 3 -C(O)-O-CH(benzyl)-C(O)-His-LVA-Ile-Amp. HR FAB MS [m + H] + : 762.4521: (70) lH-Imidazole-4-propanamide,N-[2-hydroxy-5-methyl-l-(2-methylpropyl)- 4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-α-[(l- oxo-3-phenoxypropyl)amino]-,[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-, or Phenoxy- propionyl-His-LV A-Ile-Amp ; (71) lH-Imidazole-4-propanamide,N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4- [[[2-methyl-l-[[[(2-pyridinylmethyl)amino[carbonyl[butyl[amino[carbonyl[hexyl]-α-[(l- oxo-3phenyl-2-propenyl)amino]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]- or phenyl- CH=CH-C(O)-His-LVA-He-Amp. HR FAB MS [m + H] + : 702.4343; (72) lH-Imida∞le-4-propanamide,N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4- [[[2-methyl- 1 -[[[(2-pyridinylmethyl)amino[carbonyl] [butyl]amino[carbonyl[hexyl]-α-[( 1 - oxo-4-phenyl-3-butenyl)amino]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]- or phenyl- CH=CH-CH 2 -C(O)-His-LVA-Ile-Amp. HR FAB MS [m + H] + : 716.4474; (73) 2,5,11,14-Tetraazapentadecanoic acid, 7-hydroxy-3-(lH-imidazol-4- ylmethyl)-9-(l-methylethyl)-12-(l-methylpropyl)-6-(2-methylpropyl)-4,10,13-trioxo-15-(2- pyridinyl)-,3-phenyl-2-proρenyl ester, [3S-[1(E),3R*,6R*,7R*,9R*,12R*(R*)]]- or phenyl-CH=CH-CH 2 -O-C(O)-His-LVA-Ue-Amp. HR FAB MS [m + H] + : 732.4463; (74) lH-Imida∞le-4-pιτpaιi-um^e,N-[2-hydroxy-5-memyl-l-(2-me ylpropyl)-4- [[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-α-[[(2- phenylethenyl)sulfonyl]amino]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]- or phenyl -(CH 2 ) 2 -SO 2 -His-LVA-Ile-Amp. HR FAB MS [m + H] + : 738.4061; (75) N-tert-Butyloxycart)onyl-L-phenylalanyl-L-histidyl-5S-amino-3R,4R- dihydroxy-2R-isopropyl-7-methyl-octanoyl-2S-methylbutylamideorBOC-Phe-His-LVA- Mba. FAB-MS (found): 701.4634; (76) Hydroxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or (HO)Ac-His-CVA-He-Amp. FAB-MS (found): 686.4244; (77) L-Glycyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isopropyl-hexanoyl-L-isoleucyI-2-pyridylmethylamide or Gly-His-CVA-Ile-Amp. FAB¬ MS (found): 685.4382; (78) Hydroxyacetyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R.4R- dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamide or (HO)Ac-His-CPD-He-Amp. FAB-MS (found): 734.4248; (79) Hydroxyacetyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R.4R dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamide, N-oxide or (HO)Ac-His-CPD- Ile-Amp. FAB-MS (found): 750.4202; (80) Phenoxyacetyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamideorPOA-His-CPD-Ile-Amp. FAB MS (found): 810.4557; (81) L-Glycyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R-dihydroxy hexanoyl-L-isoleucyl-2-pyridylmethylamideor Gly-His-CPD-Ile-Amp. FAB-MS (found) : 733.4409; (82) Phenoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamideorPOA-His-CVA-Ile-Amp. FAB MS (found): 762.4574; (83)l-Naphtoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R isobutyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-CLD-Ile-Amp. FAB MS (found): 826; (84) 1 -Naphthoxyacetyl-L-_ stidyl-5S-amino-6-cyclohexyl-2R-cyclohexylmethy 3R,4R-dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-CCD-Ile Amp. FAB-MS (found): 866.5189; (85) 1 -Naphthoxyacetyl-L-histidyl-5S-amino-2R-benzyl-3R,4R-dihydroxy- phenyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-PPD-Ile-Amp. FAB-MS (found): 854.4230; (86) l-N^hthoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2 isopropyl-hexanoyl-L-isoleucyl-2-pyridinylamino-ethylamideorNOA-His-CVD-Ile-Ap FAB-MS (found): 841.4964; (87)-Naphthoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-2S-cyclohexylmethy 3R,4R-dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-CcD-De-Am FAB-MS (found): 866.5194; (88) l-Naphthoxyacetyl-L-histidyl-5S-amino-3S-4S-dihydroxy-2S-isobutyl- methyl-octanoyl-L-isoleucyl-2-pyridylmethylamideorNOA-His-LlD-He-Amp. FAB-M (found): 786.4540; (89)5-Quinolinylhydroxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy- 2S-isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Qoa(b)-His-CVA-Ile-Amp. FAB-MS (found): 797: (90)4-Quinolinylhydroxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy- 2S-isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Qoa(a)-His-CVA-Ile-Amp. FAB-MS (found): 797; (91) l-Naphthoxyacetyl-L-histidyl-5S-amino-3R-4R-dihydroxy-2S-isobutyl-7- methyl-octanoyl-L-isoleucyl-2-pyridylmethylamideorNOA-His-LLd-Ile-Amp. FAB-MS (found): 786.4579; (92) 1 -Naphthoxyacetyl-L-histidyl-5S-amino-3S-4R-dihydroxy-2S-isobutyl-7- methyl-octanoyl-L-isoleucyl-2-pyridylmethylamideorNOA-His-LLd-Ile-Amp. FAB-MS (found): 786.4556; (93) l-Naphthoxyacetyl-L-histidyl-5S-amino-3R-4R-dihydroxy-2R-isobutyl-7- methyl-octanoyl-L-isoleucyl-2-pyridylmethylamideorNOA-His-LLD-Ile-Amp. FAB-MS (found): 786.4540; (94) 2-Quinolinylcarbonyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isopropyl-hexanoyl-L-isoleucyI-2-pyridinylamino-ethylamide or Qc-Asn-CVD-Ile-Apr. FAB-MS (found): 789.4670; (95) N-tert-Butyloxycarbonyl-L-alanyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamideor Boc-Ala-CVA-Ile-Amp. FAB¬ MS [ + H] + : 546; (96N-tert-Butyloxycarbonyl-L~histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamideorBOC-His-CVA-He-Amp. FAB¬ MS [m + H] + : 712; (97) -Deleted- (98) Quinolinyl-2-carbonyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or QC-His-CVA-Ile-Amp. FAB¬ MS [m + H] + : 768; (99) QuinoUnyl-2-carbonyl-L-asparaginyl-5S-amino-6-cyclohexyl-4S-hydroxy- 2S-isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or QC-Asn-CVA-Ile-Amp. FAB-MS [m +H] + : 744; •' 100) Benzyloxyca_bonyl-L-alanyl-L-alanyl-5S-anιino-6- yclohexyl-4S-hydroxy- 2S-isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamidωιCBZ-Ala-Ala-CVA-He-Amp. FAB-MS [ +H] + : 751; (101) l-Naphthalenyloxyacetyl-L-histidyl-5S-amine-6-cyclohexyl-4S-hydroxy- 2S-isopropyl-hexanoyl-L-isoleucylamideorNoa-His-CVA-Ile-NH 2 . FAB-MS [m + H] + : 705; (102) POA-His-CVA-NH-(CH 2 ) 4 -CH(CONH)(NH 2 ). FAB-MS [ + H] + : 671 ; (103) L-Asparaginamide, l-(naphthoxy)acetyl-N-[2-hydroxy-5-methyl-l-(2- methylpropyl)-4-[[[2-methyl-l-[[[2-(N-oxido)pyridinylmethyl]amino]carbonyl]butyl]ami- no]carbonyl]hexyl]-N-alpha-methyl-,[lS-[lR*,2R*,4R*(lR*,2R*)]]-orNOA-Asp-CVA- He-Amp. Mass Spectrum: No exact mass obtained because of weak M + H + ion. Other ions at m/z 665,535,348,354,236,222,157, 126,109,86; Preparations 1-4 (1) Preparation of CH 3 (OCH 2 CH 2 ) 3 OTs A 100 mL two-necked round-bottomed flask, equipped with magnetic stirring bar, nitrogen inlet and reaction thermometer, is charged with 16 mL of pyridine (Mallinckrodt) and 8.0 mL of triethylene glycol monomethyl ether (Aldrich). This solution is cooled to 0°C (ice bath) under a nitrogen atmosphere and then is treated portion wise over 20 min with 11.4 g of / oluenesulfonyl chloride so that the temperature does not exceed 5°C. About half way through the addition process a thick white precipitate began to form. Upon complete addition the resulting mixture is stirred at 0°C for two h. The mixture is poured into an ice cold solution of 30 mL of concentrated hydrochloric acid in 100 mL of water. This mixture is extracted with ethyl acetate (3 x 100 mL) and these extracts are washed with water (4 x 100 mL with the pH of the final wash being adjusted to 7 by the addition of saturated aqueous sodium bicarbonate) , combined, dried (MgSO 4 ) , filtered and concentrated under reduced pressure to give 15.54 g of the desired tosylate as a colorless oil: Η NMR (300 MHz; CDC1 3 ) δ 7.80, 7.35, 4.16, 3.69, 3.59, 3.59, 3.54, 3.35, 2.45; mass spectrum (El), ions at m/ 318 [M] + , 286, 273, 259, 243, 229, 199, 155, 91, and 59; TLC R f = 0.33 in 50% ethyl acetate/hexane (phosphomolybdic acid). This material is used without purification. (2) Preparation of 4-[CH 3 (OCH 2 CH 2 ) 3 O]-l-naphthoxyacetic acid I. Preparation of 4-[CH 3 (C<.H 2 CH 2 ) 3 O]-l-naphthol A solution of 0.50 g of 1,4-naphthalene diol (Aldrich) and 1.0 g of CH 3 (OCH 2 CH^OTs of Preparation 1 all in 10 ml of dimethylformamide is placed under a nitroge atmosphere and then cooled to -60° C. A 60% mineral oil emulsion of sodium hydride (130 mg; 3.3 mmoL) (Aldrich)is added portionwise over two minutes. The resulting mixture is allowed to stir and gradually warm to -30 α C over 1.5 h. The cooling bath is removed and the mixture is allowed to warm to room temperature over one h at which time the mixture is then heated to 50°C and stirred for one h. The reaction is quenched with IN ammonium hydroxide, diluted with methanol and concentrated under reduced pressure - first under house vacuum and then under lower pressure using a vacuum pump - to give a black colored solid. This material is dissolved in ethyl acetate and washed with brine (3X). The aqueous washes are back-extracted with ethyl acetate and the combined organic extracts are dried (Na 2 SO 4 ), filtered and concentrated to give a black colored solid (a mixture of starting diol, tosylate and desired product). This material is chromatographed over 100 g of silica gel (63-200μ), eluting with 25% acetone hexane while collecting 9 mL fractions (after a 100 mL solvent precut). Fractions 25-60 are combined and concentrated to give 0.51 g of impure 4-[CH 3 (OCH 2 CH 2 ) 3 O]-l-naphthol: TLC R f =0.19 in 25% acetone/hexane (UV). II. Preparation of 4-[CH 3 (OCH 2 CH 2 ) 3 O]-l-naphthoxyacetic acid, methyl ester The material of Section I is dissolved in 15 mL of dimethylformamide, treated with 0.32 mL of methyl bromoacetate (Aldrich), cooled to 0°C under a nitrogen atmosphere followed by treatment with 0.15 g of a 60% mineral oil emulsion of sodium hydride. The resulting green colored mixture is stirred at 0°C for 1.5 h, quenched with saturated ammonium chloride, diluted with methanol and then concentrated under reduced pressure - first under house vacuum and then under lower pressure using a vacuum pump. The resulting brown colored solid is suspended in 50 mL of water and extracted with ethyl acetate. The aqueous phase is back-washed with ethyl acetate and the combined organic extracts are dried (Na 2 SO 4 ), filtered and concentrated to give a brown colored oil (primarily a mixture of 4-[CH 3 (OCH 2 CH 2 ) 3 O]-l-naphthoxyaceticacid, methyl ester, l,4-[CH 3 (OCH 2 CH 2 ) 3 O]-naphthalene and CH 3 (OCH 2 CH 2 ) 3 OTs). This material is chromatographed over 50 g of silica gel (63-200μ), eluting with 25% acetone/hexane while collecting 9 mL fractions. Fractions 33-49 are combined and concentrated to give 285 mg of 4-[CH 3 (OCH 2 CH 2 ) 3 O]-l-naphthoxyacetic acid, methyl ester contaminated with a small amount of CH 3 (OCH 2 CH 2 ) 3 OTs: Η NMR (300 MHz; CDC1 3 ) δ 8.30-8.22, 7.56-7.50, 6.67, 6.61, 4.77, 4.25, 3.97, 3.82, 3.80, 3.69, 3.55, 3.37; TLC R f =0.31 in 25% acetone/hexane (UV). Fractions 57-80 yielded the 1,4- [CH 3 (OCH 2 CH-) 3 O]-naphthalene by-product. III. Preparation of 4-[CH 3 (OCH 2 CH 2 ) 3 O]-l -naphthoxyacetic acid The methyl ester of Section 2 (263 mg); is dissolved in 3 mL of methanol. Water (1 mL) and IN sodium hydroxide (1 mL) are added and the resulting solution is let stir at room temperature for 2 h. The solution is then poured into 10 mL of IN sodium hydroxide and extracted 3X with ethyl ether. The combined organic extracts are discarded and the aqueous phase is acidified to pH 5 with aqueous hydrochloric acid and then extracted 3X with methylene chloride. The combined organic extracts are dried (Na 2 SO 4 ), filtered and concentrated to give 187 mg of 4-[CH 3 (OCH 2 CH 2 ) 3 O]-l- naphthoxyacetic acid as a brown colored oil. TLC analysis showed only a spot at the origin using 20% ethyl acetate/chloroform. This material is used without purification in the subsequent coupling experiment. (3) Preparation of 5-[CH 3 (OCH 2 CH 2 ) 3 O]-l -naphthoxyacetic acid I. Preparation of 5-[CH 3 (OCH 2 CH 2 ) 3 O]-l-naphthoxyacetic acid, methyl ester via 5-[CH 3 (OCH 2 CH 2 ) 3 O]-l-naphthol [One pot reaction] A solution of 0.50 g of 1 ,5 -naphthalene diol (Aldrich), 1.1 g of CH 3 (OCH 2 CH 2 - ) 3 OTs of Preparation 1 and 0.27 g of a 60% sodium hydride emulsion all in 15 ml of dimethylformamide is placed under a nitrogen atmosphere and heated to 50°C. The resulting mixture is allowed to stir for 1.5 h and then treated with 0.44 mL (4.6 mmoL) of methyl bromoacetate (Aldrich). Stirring and heating is continued for an additional 1.5 h. The reaction solution is allowed to cool to room temperature and then quenched with saturated ammonium chloride, diluted with methanol and then concentrated under reduced pressure - first under house vacuum and then under lower pressure using a vacuum pump - to give a product containing mixture as a yellow solid. This solid is dissolved in ethyl acetate and washed with 50 mL of water (2X). The aqueous washes are back- washed with ethyl acetate and the combined organic extracts are dried (MgSO ), filtered and concentrated to give an orange colored oil. TLC analysis of this oil indicates a five component mixture comprised of the desired product [5-[C_^(OCH 2 CH 2 ) O]-l- naphthoxyaceticacid, methyl ester], an unidentified component, 1 ,5-[CH 3 (OCH 2 CH 2 ) 3 O]- naphthalene, l,5-[CH 3 O 2 CCH 2 O]-naphthalene and 5-[CH 3 (OCH 2 CH 2 ) 3 O]-l-naphthol. This mixture is chromatographed over 50 g of silica gel (63-200μ), eluting with 20% ethyl acetate/chloroform while collecting 6 mL fractions. Fractions 51-60 are combined and concentrated to give 241 mg of 5-[CH 3 (OCH 2 CH 2 ) 3 O]-l -naphthoxyacetic acid, methyl ester: Η NMR (300 MHz; CDC1 3 ) β 7.92, 7.91, 7.37 , 7.31, 6.83, 6.71, 4.78, 4.25, 3.95, 3.77, 3.79, 3.67, 3.52, 3.35; TLC R^O.46 in 20% ethyl ace¬ tate chloroform (UV). II. Preparation of 5-[CH 3 (OCH 2 CH 2 ) 3 O]-l -naphthoxyacetic acid The methyl ester of Section I (241 mg; 0.63 mmoL) is dissolved in 3 mL of methanol. Water (1 mL) and IN sodium hydroxide (1 mL) are added and the resulting solution is let stir at room temperature for 2 h. The solution is then poured into 10 mL of IN sodium hydroxide and extracted 3X with ethyl ether. The combined organic extracts are discarded and the aqueous phase is acidified to pH 5 with aqueous hydrochloric acid and then extracted 3X with methylene chloride. The combined organic extracts are dried (Na 2 S0 4 ), filtered and concentrated to give 206 mg of 5-[CH 3 (OCH 2 C- H 2 ) 3 O]-l-naphthoxyacetic acid as a brown colored oil. TLC analysis showed only a spot at the origin using 20% ethyl acetate/chloroform. This material is used without purification in the subsequent coupling experiment. (4) Preparation of H-Asn-CVA-Ile-Amp. A solution of 134 mg of Boc-L-Asparagine (Sigma) and 202 mg of H-CVA-He- Amp all in 10 mL of dimethylformamide is treated with 370 μL of diisopropylethylamine (Aldrich) followed by treatment with 160 μL of diethyl cyanophosphonate (Aldrich). The resulting solution is stirred under a nitrogen atmosphere for 17 h at which time TLC analysis confirmed the coupling is complete. The solution is transferred with washing with methanol to a 1 -necked (24/40) 200 mL round-bottomed flask and then concentrated on a rotary evaporator - first under house vacuum and then under lower pressure using a vacuum pump - to give the crude Boc-Asn-CVA-Ile-Amp. This material is suspended in a solution of 3 mL of methylene chloride and 3 mL of trifluoroacetic acid (Aldrich). The resulting yellow colored mixture is stirred at room temperature for 2 h and then concentrated under reduced pressure. This material (preabsorbed on » 2 g of silica gel) is chromatographed over 55 g of silica gel (63-200μ), eluting with 10% (4M NH 3 /MeO- H)/CHC1 3 while collecting 6 mL fractions. Fractions 51-86 are combined and concentrated to give 158 mg of product: mass spectrum (FAB) ions at mlz 589[M+H] + , 571, 481, 236, 222, 126, 109, 86 and 69. TLC R f =0.32 in 10% (4M NH 3 /MeOH)/CH- Cl 3 (UV). Examples 104-105 (104) L-Asparaginamide, [5-(triethyleneglycol monomethyl ether)naphthoxy]acetyl-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[[2- (N-oxido)pyridinylmethyl]amino]carbonyl]butyl]amino]carbonyl]hexyl]-N-alpha-methyl-, [lS-[lR*,2R" [ ,4R*(lR ,,t ,2R*)]] or 5-[CH 3 (OCH 2 CH 2 ) 3 O]-l-Noa-Asn-CVA-Ile-Amp. A solution of 47.6 mg (0.131 mmoL) of 5-[CH 3 (OCH 2 CH 2 ) 3 O]-l-naphthoxya- cetic acid of Preparation 3 and 50.7 mg of H-Asn-CVA-Ile-Amp of Preparation 4 all in 3 mL of dimethylformamide is treated with 74 μL of diisopropylethylamine (Aldrich) followed by treatment with 32 μL of diethyl cyanophosphonate (Aldrich). The resulting solution is stirred under a nitrogen atmosphere for 13 h at which time TLC analysis confirmed the coupling is complete. The solution is transferred with washing with methanol to a 1 -necked (24/40) 200 mL round-bottomed flask and then concentrated on a rotary evaporator - first under house vacuum and then under lower pressure using a vacuum pump - to give the crude product as a yellow solid. This material (preabsorbed on * 2 g of silica gel) is chromatographed over 50 g of silica gel (63-200μ), eluting with 8% (4M NH 3 /MeOH)/CHCl 3 while collecting 6 mL fractions. Fractions 16-30 are combined and concentrated to give the desired product contaminated with a less polar impurity. This material is rechromatographed in a similar fashion using 6% (4M NH 3 /MeOH)/CHCl 3 . Fractions 44-54 are combined and concentrated to give 24.8 mg the product with a purity of > 99%: mass spectrum (FAB) [M+Hj + found: 935.5476; other ions at m/z 827, 416, 367, 348, 330, 318, 305, 236, 222, 177, 126, 109, and 86. HPLC retention time = 18.6 min. TLC R f =0.53 in 10% (4M NH 3 /MeOH)/CHCl 3 (UV). Fractions 34-43 afforded additional amounts of slightly less pure material. (105) L-Asparaginamide, [4-(triethyleneglycol monomethyl ether)naphthoxy]acetyl-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[[2- (N-oxido)pyridinylmemyl]amino]ca_ x)nyl]butyl]amino]carbonyl]hexyl]-N-alpha-methyl-, [1S-[1R*,2R*,4R*(1R*,2R*)J] or 4-[CH 3 (OCH 2 CH 2 ) 3 O]-l-Noa-Asn-CVA-He-Amp A solution of 52.6 mg of 4-[CH 3 (OCH 2 CH 2 ) 3 O]-l -naphthoxyacetic acid of Preparation 2 and 51.0 mg of H-Asn-CVA-He-Amp of Preparation 4 all in 3 mL of dimethylformamide is treated with 75 μL of diisopropylethylamine (Aldrich) followed by treatment with 32 μL of diethyl cyanophosphonate (Aldrich). The resulting solution is stirred under a nitrogen atmosphere for 25 h at which time TLC analysis confirmed the coupling is complete. The solution is transferred with washing with methanol to a 1-necked (24/40) 200 mL round-bottomed flask and then concentrated on a rotary evaporator - first under house vacuum and then under lower pressure using a vacuum pu p - to give the crude product as a yellow solid. This material (preabsorbed on ~ 2 g of silica gel) is chromatographed over 50 g of silica gel (63-200μ). eluting with 6% (4M NH ? /MeOH)/CHCl 3 while collecting 6 mL fractions. Fractions 39-57 are combined and concentrated to give 70.2 mg the product with a purity of > 99% : mass spectrum (FAB) [M+Hr found: 935.5494; other ions at m/z 827. 348. 330. 318, 305. 236. 222, 147, 126, 109, and 86. HPLC retention time = 17.6 min. TLC R f =0.55 in 10% (4M NH 3 /MeOH)/CHCl 3 (UV). Examples 106-107 (106) L-Glycyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R-isopropyl- hexanoyl-=L-isoleucyl-2-pyridylmethylamide-or Gly-CVD-Ile-Amp. FAB-MS (found): 548.3844; (107) L-Glycyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R-dihy- droxy-hexanoylL-isoleucyl-2-pyridyl-methylamide or Gly-CPD-Ile-Amp. FAB-MS (found): 596.3835. Table I Preparation of the Compounds Useful in the Present Invention Compound of Example No. Publication PCT Pub. No. WO87/02986 (21 May 1987); PCT International Application WO 87/5909 (8 Oct. 1987): S. Thaisrivongs et al., J. Med. Chem., 31 (7), 1369-76; S. Thaisrivongs et al. , J. Med. Chem. , 29 (10), 2088-93. EPO Pub. Appl. 0173481 (5 March 1986) Prep. C59, C66 PCT Pub. No. WO86/06379 (6 November 1986) Example 10 PCT Pub. No. WO86/06379 (6 November 1986) Example 10 PCT Pub. No. WO86/06379 (6 November 1986) Example 9 EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) PCT Pub. No. WO87/05302 (11 September 1987) Example 6 PCT Pub. No. WO87/05302 (11 September 1987 Example 7 PCT Pub. No. WO87/05302 (11 September 1987 Example 12 PCT Pub. No. WO87/05302 (11 September 1987 Example 15 EPO Pub. Appl. 0173481 (5 March 1986) Table I (continued) Preparation of the Compounds Useful in the Present Invention Compound of Example No. Publication (12) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) (13) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) (14) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) (15) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) (16) PCT Pub. No. WO87/05302 (11 September 1987) Example 12 PCT Pub. No. WO87/05302 (11 September 1987) PCT Pub. No. WO89/00161 (12 January 1989 Example 2 EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) EPO Pub. Appl. 0173481 (5 March 1986); D.E. Epps, Anal. BioChem., 181 (1), 172-81. EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) EPO Pub. Appl. 0173481 (5 March 1986) Table I (continued) Preparation of the Compounds Useful in the Present Invention Compound of Example No. Publication 10 (23) PCT Pub. No. WO87/02986 (21 May 1987) (24) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) 15 (25) PCT Pub. No. WO87/02986 (21 May 1987); EP Pub. Appl. 0173481 (5 Marth 1986) PCT Pub. No. WO87/02986 (21 May 1987) PCT Pub. No. WO87/02986 (21 May 1987) PCT Pub. No. WO87/02986 (21 May 1987) PCT Pub. No. WO87/02986 (21 May 1987) PCT Pub. No. WO87/02986 (21 May 1987) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) PCT Pub. No. WO87/02986 (21 May 1987) PCT Pub. No. WO87/02986 (21 May 1987) PCT Pub. No. WO87/02986 (21 May 1987) PCT Pub. No. WO87/02986 (21 May 1987) 45 Table I (continued) Preparation of the Compounds Useful in the Present Invention Compound of Example No. Publication (65) PCT Pub. No. WO87/02986 (21 May 1987) (66) PCT Pub. No. WO87/02986 (21 May 1987) (67) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) (68) PCT Pub. No. WO87/02986 (21 May 1987) (69) EPO Pub. Appl. 0173481 (5 March 1986) PCT Pub. No. WO87/02986 (21 May 1987) Table II Compound of HIV Protease Inhibitor Activity Example No. Kj(nM) (1) 60% at 10^ (2) < 10 (3) 94% at 2.5 x lO "7 (4) 90% at 2.5 x 10- 7 (5) 73% at 2.5 x 10- 7 (6) 10 (7) < < 10 (8) 15% at 2.5 x 10- 7 (9) 100% at 2.5 x lO "7 (10) < < 10 (11) 14 (12) 7 (13) 45% at lO "7 (14) 51 % at lO "7 (15) 76% at 5 x lO "7 (19) 48% at 5 x 10 "8 (20) 480 (21) 4.3 (22) 148 (23) 88 (24) 74 (25) 30% at lO^M (26) 28 (27) 800 (28) 8 (29) 70 Table in Upjohn HIV Protease Inhibitors Tested for Antiviral Activity (DIAGEN) 100% (p24 synthesis) on day-4 72% (RNA synthesis) on day-4 STRUCTURE CHART X-C 8 -D 9 -E 10 -F 11 -G 1 2-Z *6 \ / CH CH 0 -0 c- ΣLη , X . XL2- X^b -59- STRUCTURE CHART (continued) R ώ CH C ! I I : — N — CH — C — XL. ∑Lβd XLβi STRUCTURE CHART (continued) II III XLβ' X^c 1 XLδd 1 XLe, STRUCTURE CHART (continued) π' m' IV' Xl« XL4, ) t XXXI XXX 0H ^ — -. -CH 2 -C (CH-OR 121 ) w XXXII ^-O^CH I R]. 8_ or

Claims: CLAIMS 1. Use of a compound of formula I X-Cg-ϋ 9 -.b I o--'"ιι-(_-j 1 -Z. 1 to prepare a medicament for inhibiting a retrovirus in a mammalian cell infected with said retrovirus; wherein X is a) -(CH^-aryl, b) -(CH^-Het, c) -(CH 2 ) p -C 3 -C 7 cycloalkyl, d) R s -O-(CH) 2q -C(O)-, e) R s -CH,-O-C(O)-, f) R 5 -O-C(O)-, g) R s -(CH 2 λ,-C(0)- I h) R 5 -(CH 2 ) n -C(S)-, i) R 4 N(R 4 )-(CH 2 ) n -C(O)-, k) R s -SO 2 -(CH 2 ) q -O-C(O)-, 1) Rs-CCH^-SC^, m) Z-C(O)-CH(OH)-CH(CH 2 R,)-C(O)- n) RHCH^ CH=CH-(CH 2 ) p -C(O)-, o) R 5 (CH 2) p CH=CH-(CH 2 ) p -O-C(O), or p) R^CH^-CCO)-; wherein C g is absent or a divalent moiety of the formula XL j , XL j , XL^, XL^ or othe amino acyl derivative; *4 XLx — 2. *L2b wherein D 9 is a divalent moiety of the formula XI^, XL^, X or other amino acyl derivative; R 20 — N — CH 2 — C(0) . «*« ∑L∑ wherein E I0 -F π is a divalent moiety of the formula XI^, XL^, XL & , XL**, X ^, H, III XL* XL* π m wherein Gj 2 is absent or a divalent moiety of the formula XL 4 , XL 4l or other amino acy derivative; XL ^α*. wherein Z is a) -O-R JO , a) -COOH, b) -COOC,-C 6 alkyl, c) -CONR 22 R 26 , or d) -CHfNHjJCOOH: wherein R πo is a) R 126 C[(CH 2 ) q OR 121 ] 2 (CH 2 ) q -, d) -CH 2 (CHOR 12l ) x CH 2 OR 121 , e) R, 2 _OCH 2 (CHOR 121 ) v CH-(CHOR 121 ) z CH 2 OR 121 , XXXII ,or wherein j is one to three, inclusive; wherein m is one or two; wherein p is zero to two, inclusive; wherein r is zero to five, inclusive; wherein for each occurrence n is independently an integer of zero to five, inclusive; wherein q is an integer of one to five, inclusive; wherein u is an integer of zero to three, inclusive; wherein v is an integer of zero to four, inclusive; wherein s is an integer of zero or one so that the sum of u plus v plus s is three or fou wherein t is an integer of zero to three, inclusive; wherein w is an integer of two or three; wherein x is an integer of two to seven, inclusive; wherein y is an integer of zero to six, inclusive; and wherein z is an integer of zero to six so that the sum of y plus z does not exceed six wherein aryl is phenyl or naphthyl substituted by zero to three of the following: a) -Cjalkyl, b) hydroxy, c) Cj- alkoxy, d) halo, e) amino, f) mono- or di- - alkylamino, g) -CHO, h) -COOH, i) COOR 26 , j) CONHR 26 , k) nitro, 1) mercapto, m) C r C 3 alkylthio, n) Ci- alkylsulfinyl, 0) C r C 3 alkylsulfonyl, p) -Nfl- -q-Cjalkylsulfmyl, q) -SO 3 H, r) SO 2 NH 2 , s) -CN, or t) -CH 2 NH 2 ; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle and the ring may be connected through a carbon or secondary nitrogen in the ring or an exocyclic nitrogen; and if chemically feasible, the nitrogen and sulfur atoms may be in the oxidized forms; and optionally substituted by zero to three of the following: a) C r C 5 alkyl, b) hydroxy, c) hydroxy (C C 5 alkyl), d) halogen, e) amino, f) amino (C r C 5 alkyl), g) -CHO, h) -CO-H, i) -CO 2 -(C r C 5 alkyl), j) -CONH 2 , k) -CONH-(C r C 5 alkyl), 1) nitro, m) mercapto, n) mercapto (Cι-C 5 alkyl), 0) -SO 3 H, p) -SO 2 NH 2 , q) -CN, r) -O-CrCjalkyl, or s) -[CKCH J W.-OCH J ; with the provisos that: 1) G 12 is present when both C g and D 9 are present and Eio-Fn is other than LPA; 2) when X is Z-C(O)-CH(OH)-CH(CH 2 R,)-C(O)-, D 9 is His and G 12 is He; 3) when X is R 5 -CH 2 -O-C(O)-or R J -(CH 2 ) n -C(O)- and E 10 - F„ is XLβ, XLβ b , XL & or XL*,, R 5 is other than C r C 6 alkyl; 4) when X is R 5 -O-C(O)- and E, 0 -F n is XL*, X *, L& or XL^, R 5 is other than C,-C 6 alkyl, C 3 -C 7 cycloalkyl or aryl; 5) when X is R 5 -(CH 2 ) n -C(O)-wherein R s is cycloalkyl or aryl, and E, 0 F n is XLή, X-U t ,, XL* or XL < _, n is other than one; 6) when X is R 4 N(R 4 )-(CH 2 ) n -C(O)- and E10-F,, is XL 6 , XL«., XL & or XLβj, n is other than one; 7) Z is other than N-4-amino-2-methyl-5-pyrimidinylmethyl-amide; 8) X is other than benzyloxycarbonyl or butyloxycarbonyl, when Ej 0 -F u is II or IV; and 9) when X is R s -(CR^) B -C(0)- and E 10 -F n is II or IV, R 5 is other than C,- Q alkyl. 2. The use of claim 1 wherein E 10 -F π is a divalent moiety of the formula XIV, X > X . XLβd', XL f c', ir, III', or IV'; X ' XL*' X * XL*,' XL ' π' πr IV wherein the variables are as defined in claim 1. The use of claim 1 wherein the cell is in a human. 4. The use of claim 3 wherein diseases caused by said retrovirus are treated in said human. 5. The use of claim 4 wherein C 8 , D 9 and G 12 are present. 6. The use of claim 5 wherein the compound of formula I is selected from the group consisting of: lH-Imidazole-4-propanamide, c.-[[2-(acetyloxy)-3-(l-naphthalenyl)-l- oxopropyl]amino]-N-[l-(cyclohexylmethyl)-3,3-difluoro-4-[[2-methyl-l-[[(2-pyridinyl methyl)amino]carbonyl]butyl]amino]-2,4-dioxobutyl]-, [lS-[lR*[αR*(R*)],2R*]]-; L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-pheny_alanyl-N-[l (cyclohexylmethyl)-3,3-difluoro-4-[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl] butyl]amino]-2,4-dioxobutyl]-; or Boc-Phe-His-LFA-Ile-Amp; and L-α-Glutamine,N/u2/d-[N-[[l, l-dimethylethoxy)carbonyl]-L-phenylal anyl]-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinyl methyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*,2R*4R ,,, (lR*, -2R*)]]-,monacetate (salt) or BOC-Phe-Glu-LVA-Ile-Amp. 7. The use of claim 4 wherein C g is absent, D 9 is present and G 12 i present. 8. The use of claim 7 wherein the compound of formula I is selected fro the group consisting of: lH-Imidazole-4-propanamide, N-[2-hydroxy-5-methyl-l-(2-methyl propyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]h xyl]-α-[(phenoxyacetyl)-amino]-, [1S-[1R*,2R*,4R*(1R*,2R*)]]- ; POA-His-LVA-Ile Amp; lH-Imidazole-4-propanamide, N-[l-(cyclohexylmethyl)-3,3-difluoro- [[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]-2,4-dioxobutyl]-Q!-[[( naphthalenyloxy)acetyl]amino]-, [1S-(1R*(C_R*),2R*]]-; or NOA-His-LFA-He-Amp; lH-Imidazole-4-propanamide, N-[l-(cyclohexylmethyl)-2-hydroxy- methyl-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]he tyl]-α-[(phenoxyacetyl)amino]-, [1S-[1R*(R*),2R*,4S*(1R*,2R*)]]-; or POA-His-CLA Ile-Amp; lH-Imidazole-4-propanamide, N-[2,3-dihydroxy-5-methyl-l-(2- methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]car- bonyl]hexyl]-c_-[(phenoxyacetyl)amino]- [1S-[1R*(R*),2S*,3R*,4R*(1R*,2R*)]]-; or POA-His-LVD-Ile-Amp; 1-Noa-His-Cha PSI[CHOHCHOH]Val-Ile-Amp; or lH-Imidazole-4- propanamide, N-[l-(cyclohexylmethyl)-2,3-dihydroxy-5-methyl-4-[[[2-methyl-l-[[(2- pyridinylmethyl)amino]carbonyl]butyl]-[amino]carbonyl]hexyl]-c_-[[(l-naphthalenyloxy)ac- etyl]amino]-, [1S-[1R*(R*),2S*,3S*,4S*(1R*,2R*)]]-; or NOA-His-CVD-Ile-Amp; lH-Imidazole-4-propanamide, N-[2-hydroxy-6-methyl-l-(2-methyl- piOpyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hep- tyl]-c_-[(phenoxyacetyl)amino]-, [1S-[1R*(R*),2R*,4S*(1R*,2R*)]]-; or POA-His-LLA- Ile-Amp; lH-Imidazole-4-propanamide, N-[2-hydroxy- 1 -(2-methylpropyl)-5-[[2- memyl-l-[[(2-pyridinylmemyl)_unino]carbonyl]butyl]amino]-5-oxo-4-(phenylmethyl)pen- tyl]-c--[(phenoxyacetyl)amino]-JlS-[lR*(R*),2R*,4S*,5(lR*,2R*)]]-prPOA-His-LPA- Ile-Amp; 1 H-Imid__zole-4-propanamide,N-[4-(cyclohexylmethyl)-2-hydroxy- 1 -(2- methylpropyl)-5-[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]-5- oxopentyl]-α-[(phenoxyacetyl)amino]-, [1S-[1R*(R*),2R*,4S*,5(1R*,2R*)]]-; or POA- His-LCA-Ile-Amp; lH-Imidazole-4-propanamide, N-[l-(cyclohexylmethyl)-2-hydroxy-5- methyl-4-[[[2-me yl-l-[[(2-pyridinylmethyl) -- in o]carbonyl]butyl]ammo]carbonyl]hexyl]- α-[(phenoxyacetyl)amino]-, [1S-[1R*(R*),2R*,4R*(1R*,2R*)]]-; or POA-His-CVA-Ile- Amp; lH-Imidazole-4-propanamide, N-[l-(cycloheptylmethyl)-2-hydroxy-5- methyl-4-[[[2-methyl-l-[[(2-pyridinylmethyl)am o]caιbonyI]butyl]aπ_ino]ca-bonyl]hexyl]- c--[(phenoxyacetyl)amino]-,[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-prPOA-His-chpVA-Ile- Amp; Nc_-[(2S,4S,5S)-5-[N-[Nc_-(Phenoxymethylcarbonyl)-L-histidyl]amino-4 hydroxy-2-isopropyl-7-methyl-l-oxooctyl]-N-[2-(2-pyridinylamino)ethyl]-L-isoleucin- amide, acetic acid salt; or POA-His-LVA-Ile-NH(CH 2 ) 2 NH-pyridine; Nc_-[(2S ,4S ^SJ-S-fN-tNα-^henoxymemylcaiiDonylVL-histidyllainino]^ hydroxy-2-isopropyl-7-methyl-l-oxooctyl]-N-(2,3-dihydroxypropyl)-L-isoleucinamide; or POA-His-LVA-Ile-NH-CH 2 -CH(OH)-CH 2 OH; Nα-[(2S ,4S ,5S)-5-[ J-{Nc_-(Phenoxyme ylcarbonyl)-L-histidyl]-amino-4- hydroxy-2-isopropyl-7-methyl-l-oxooctyl]-N-(2-hydroxypropyl)-L-isoleucinamide; or POA-His-LVA-Ile-NH-CH 2 -CH(CH 3 )(OH); Nα-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]- 6-cyclohexyl-4-hydroxy-2-i_opropyl-l-oxohexyl]-N-(2-pyridinylme yl)-L-isoleud-___-ιide, pyridine N-oxide or NOA-His-CVA-Ile-Amp-NO; Nα-[(2S, 4S, 5S)-5-[N-[Nα-(f-toluenesulfonyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide or p-Tolunesulfonyl-His-CVA-Ile-Amp; Nα-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]- 6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide or NOA-His-CVA-Ile-Amp; Nα-[(2S,4S^S)-5-[N-[Nα-(Phenoxymethylcarbonyl)-L-histidyl]amino]- 6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmemyl)-L-isoleucinamide, pyridine N-oxide or POA-His-CVA-He-Amp-NO; Nα-[(2S, 4S, 5S)-5-[N-[N__-(p-Toluenesulfonyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide, pyridine N-oxide or p-Toluenesulfonyl-His-CVA-Ile-Amp-NO; Nα-[(2S, 4S, 5S)-5-[N-[Na-(l-Naphthalenyloxyacetyl) (2-pyridinyl)ala- nyl]amino]-6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L- isoleucinamide or NOA-His-CVA-Ile-Amp; Nα-[(2S, 4S, 5S)-5-[N-[Nα-[(3-Pyridinyl)-methylcarbonyl]-L-histidyl]- amino]-6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L- isoleucinamide or (3-pyridinyl)-methyl-carbonyl-His-CVA-Ile-Amp; Ne-[N 2 -[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]- amino]-6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-L-isolencyl]-L-lysine, triflouroacetic acid salt or NOA-His-CVA-Ile-L-lysine, trifluoroacetic acid salt; Nα-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]- 6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-[2-(2-pyridinylamino)ethyl]-L- isoleucinamide or NOA-His-CVA-He-NH-(CH 2 ) 2 -NH-(2-pyridine); lH-Imidazole-4-propanamide,N-[2-hydroxy-4-[[[l-[[(2-hydroxy-2- phenylethyl)amino]carbonyl]-2-methylbutyl]amino]carbonyl]-5-methyl-l-(2-methyl- propyl)hexyl]-c_-[(phenoxyacetyl)amino]-, monoacetate (salt) or POA-His-LVA-Ile-NH- CH 2 -CH(OH)-phenyl; Pentanoic acid, 5-[[l-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[2- meΛyl-l-[[(2-pyridinylme yha_τ_ino]carbonyl]butyl]amm^^ indol-2-ylcarbonyl)amino]-5-oxo-,[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-orlH-indol-2-yl- carbonyl-Glu-CVA-Ile-Amp; L-.alpha.-Glutamine, N-[l-(cyclohexylmethyl)-2-hydroxy-5-methyl-4- [[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-N/!&/d- L-phenylalanyl-, [1S-[1R*,2R*,4R*(1R*,2R*)]]-, bis(trifluoracetate) (salt) or Phe-Glu- CVA-He-Amp; 2-Pyridineacetamide, N-[2-[[2-hydroxy-5-methyl-l-(2-methylpropyl)-4- [[[2-memyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]amino]-l- (lH-imidazol-4-ylmethyl)-2-oxoethyl]-[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-or (2- Pyridyl)acetyl-His-Lva-Ile-Amp; 4-Pyridineacetamide, N-[2-[[2-hydroxy-5-methyl- 1 -(2-methylpropyl)-4- [[[2methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]amino]-l- (lH-imidazol-4-ylmethyl)-2-oxoethyl]-[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-or (4- Pyridyl)acetyl-His-LVA-Ile-Amp; lH-Indole-2-carboxamide, N-[2-([2-hydroxy-5-methyl-l-(2-methylpr- opyl)-4-[[2-memyl-l-[[(2-pyridinylmemyl)amino]carbonyl]butyl]carbonyl]hexyI]amino]-l- (lH-imidazoM-ylmethyl)-2-oxoethyl]-,[lS-[lR*(R*),2R*,4R*(lR' ,t ,2R*)]]- or N-(Indolyl- 2-carbonyl)-His-LV A-Ile-Amp ; 2,5,11,14-Tetraazapentadecanoic acid, 7-hydroxy-3-(lH-imidazol-4- ylmemyl)-9-(l-me ylethyl)-12-(l-πEthylprcφyl)-6-(2-memylpropyl)-4,10,13-trioxc>-15-(2- pyridinyl)-,4-pyridinylmethyl ester, [3S-[3R*,6R*,7R*,9RM2R*(R*)]]- or Ioc-His- LVA-He-Amp; lH-Imidazole-4-propanamide, N-[2-hydroxy-5-methyl-l-(2-methyl- propyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]- carbonyl]butyl]amino]carbonyl]hexyl]-α-[(l-oxo-3-phenoxypropyl)amino]-,[lS- [lR*(R*),2R*,4R*(lR*,2R*)]]-,orPhenoxypropionyl-His-LVA-Ile-Amp; lH-Imidazole -propanamide,N-[2-hydroxy-5-methyl-l-(2-me_hylpropyl)- 4-[[[2-me yl-l-[[[(2-pyridmylmemyl)amino[<^ιrbonyl[butyl[anino[c__rbonyl[hexyl]-α-[(l- oxo-3phenyl-2-propenyl amino]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]- or phenyl- CH = CH-C(O)-His-LV A-Ile- Amp ; lH-Imidazole^-propanamide,N-[2-hydroxy-5-methyl-l-(2-methylpropyl)- 4-[[[2-memyl-l-[[[(2-pyridinylmewyl)__πι_no[ca_τ_^ oxo-4-phenyl-3-butenyl)amino]-,[lS-[lR*[R*(E)].2R*,4R*(lR*,2R*)]]- or phenyl- CH = CH-CH 2 -C(O)-His-LVA-Ile-Amp; 2,5,11,14-Tetraazapentadecanoic acid, 7-hydroxy-3-(lH-imidazol-4- ylme yl)-9-(l-memylethyl)-12-(l-methylpropyl)-6-(2-methylpropyl)-4,10,13-trioxo-15-(2- pyridinyl)-,3-phenyl-2-propenyl ester, [3S-[1(E),3R*,6R*,7R*,9R*,12R*(R*)]]- or phenyl-CH=CH-CH 2 -O-C(O)-His-LVA-Ile-Amp; U-77407 lH-Imida_M)le^-prop___in_ide,N-[2-hydroxy-5-me_hyl-l-(2-methylpropyl)- 4-[[[2-me yl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-α-[[(2- phenylethenyl)sulfonyl]amino]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]-orphenyl-(CH 2 )- Hydroxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or (HO)Ac-His-CVA-Ile-Amp; Hydroxyacetyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R- dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamide or (HO)Ac-His-CPD-Ile-Amp; Hydroxyacetyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R- dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamide,N-oxideor(HO)Ac-His-CPD-He- Amp; Phenoxyacetyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R- dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamide or POA-His-CPD-Ile-Amp ; Phenoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or POA-His-CVA-He-Amp; l-Naphtoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy- 2R-isobutyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-CLD-Ile-Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-2R-cyclohexylme- thyl-3R,4R-dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamidθ iNOA-His-CCD-He- Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-2R-benzyl-3R,4R-dihydroxy-6- phenyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-PPD-He-Amp; l-Naphthoxyacεtyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy- 2R-isopropyl-hexanoyl-L-isoleucyl-2-pyridinylamino-ethylamide or NOA-His-CVD-Ile- Apr; l-Naphthoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-2S-cyclohexylme- thyl-3R,4R-dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamidoDiNOA-His-CCD-He- Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-3S-4S-dihydroxy-2S-isobutyl-7- methyl-octanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-LID-Ile-Amp ; l-Naphthoxyacetyl-L-_tistidyl-5S-amino-3R-4R-dihydroxy-2S-isobutyl-7- methyl-octanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-LID-Ile-Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-3S-4R-dihydroxy-2S-isobutyl-7- methyl-octanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-LID-Ile-Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-3R-4R-dihydroxy-2R-isobutyl-7- methyl-octanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-LID-Ile-Amp ; 2-Quinolinylcarbonyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isopropyl-hexanoyl-L-isoleucyl-2-pyridinylamino-ethylamide or Qc-Asn-CVD-Ile-Apr; C iinolinyl-2-carbonyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or QC-His-CVA-Ile-Amp; Quinolinyl-2-carbonyl-L-a-φaraginyl-5S-amino-6-cyclohexyl-4S-hydroxy- 2S-isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or QC-Asn-CVA-Ile-Amp; 1 -Naphthalenyloxyacεtyl-L-histidyl-5S-amine-6-cyclohexyl-4S-hydroxy- 2S-isopropyl-hexanoyl-L-isoleucylamide or Noa-His-CVA-Ile-NH 2 ; L-Asparaginamide, l-(naphthoxy)acetyl-N-[2-hydroxy-5-methyl-l-(2- methylpropyl)-4-[[[2-methyl-l-[[[2-(N-oxido)pyridinylmethyI]amino]carbonyl]butyl]ami- no]carbonyl]hexyl]-N-alpha-methyl-,[lS-[lR*,2R*,4R*(lR*,2R*)]]-orNOA-Asp-CVA- He-Amp; L-Asparaginamide, [5-(triethyleneglycol monomethyl ether)naphthoxy]acetyl-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[[2- (N-oxido)pyridinylmethyl]amino]carbonyl]butyl]amino]carbonyl]hexyI]-N-alpha-methyl-, [1S-[1R*,2R*,4R*(1R*,2R*)]]-OΓ 5-(triethyleneglycol monomethyl ether-NOA-Asp-CVA- He-Amp; and L-Asparaginamide , [4-(triethyleneglycol monomethyl ether)naphthoxy]acetyl-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[[2- (N-oxido)pyridinylmemyl]amino]cariκ nyl]butyl]___ ino]carrx)nyl]hexyl]-N-_dpha-methyl-, [1S-[1R*,2R*,4R*(1R*,2R*)]]- or 4-(triethyleneglycol monomethyl ether)-NOA-Asp- CVA-Ile-Amp; 9. The use of claim 4 wherein C 8 is absent, D 9 is present and G is absent. 10. The use of claim 9 wherein the compound of formula I is selected from the group consisting of: lH-Imidazole-4-propanamid^.-[2,3-dihydroxy-5-methyl-4-[[(2-methyl- butyl)amino]carbonyl]-l-(2-methylpropyl)hexyl]-α-[(phenoxyacetyl)amino]-, [1R- [1R*(S*),2S*,3S*,4S*(S*)]]-; or POA-His-LVDA-Mba; Ne-[(2S,4S^S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]- 6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyI]-L-lysine,triflouroacectic acid salt or NOA-His-CVA-L-lysine,triflouroacetic acid salt; N-[(2S,4S,5S)-5-[N-[N -(l-Naphthalenyloxyacetyl)-L-histidyl]amino]- 6-cyclohexyl-4-hydroxy-2-i_opropyl-l-oxohexyl]-N-[2-(2-pyridinylamino]ethyl]-aminβr NOA-His-CVA-NH-(CH 2 ) 2 -NH-(2-pyridine); N-[(2S , 4S , 5S)-5-[N-[Nα-( l-Naphthalenyloxyacetyl)-L-histidyl]amino]- 6-cyclohexyl-4-hydroxy-2-isopropyl- 1 -oxohexyl]-N-[2-(2-pyridinylamino)]ethyl]amine, - pyridine N-oxide or NOA-His-CVA-NH(CH 2 ) 2 -NH-(2-pyridine); Pentanoic acid, 5-[ri-(cyclohexylmethyl)-2-hydroxy-4-[[(2-hydroxy- propyl)amino]carbonyl]-5-methylhexyl]amino]-5-oxo-4-[(phenoxyacetyl)amino]-orPOA- Glu-C V A-NH-CH 2 CH(CH 3 )(OH) ; lH-__midazole-4-propanamide, N-[l -(cyclohexylmethyl)-2-hydroxy-4-[[(2- hydroxypropyl)amino]carbonyl]-5-methylhexyl]α-[(phenoxyacetyl)amino]-, monoacetate (salt) or POA-His-CVA-NH-CH 2 -CH(OH)(CH 3 ); N-tert-Butyloxycarbonyl-L-phenylalanyl-L-histidyl-5S-amino-3R,4R- dmydroxy-2R-isopropyl-7-memyl-oc__noyl-2S-methylbutylamideorBOC-Phe-His-LVA- Mba; and POA-His-CVA-l^H-(CH 2 ) 4 -CH(CONH)(NH 2 ) ; 11. Use of a compound selected from the group consisting of: L-Isoleucinamide, l^-(5-amincH4-hydroxy-2-(l-methylethyl)-l-oxooctyl]- N-(2-pyridinylmethyl)-, trifluoroacetate, (S,S,S)-; or H-LVA-He-Amp; Octanamide5-[(3.3-dimethyl-l-oxobutyl)amino]-4-hydroxy-7-methyl-2- (l-methylethyl)-N-[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]- ( [2S- [1(1R*,2R*).2R*,4R*,5R*]]- or TBA-LVA-Ile-Amp; Cyclohexanehexanamide, δ-[(3,3-dimethyl-l-oxobutyl)amino]-r-hydroxy- α-(l-methylethyl)-N-[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]-, [αS- [N(lR*,2R*),αR*,τR*,δR*]]- or TBA-CVA-Ile-Amp; Cyclohexanehexanamide, δ-amino-τ-hydroxy-c_-(l-methylethyl)-N-[[2- methyl-l-[[(2-pyridinylmethyl)]amino]carbonyl]butyl]-dihydrochloride,[αS-[N(lR*,2R- *),αR*,τR*,δR*j]- or H-CVA-He-Amp; Cyclohexanehexanamide, δ-(acetylamino)-τ-hydroxy-c--(l-methylethyl)- N-[2-methyl-l-[[(pyridinylmethyl)amino]carbonyl]butylI S-[N(lR*,2R*),αR*,τR*,δR- *]]-; or Ac-CVA-Ile-Amp; Octanamide, 5-(acetyl__mino)-4-hydroxy-7-methyl-2-(l-methylethyl)-N-[2- memyl-l-[[(2-pyridinylmethyl)amino)carbonyl]butyl]-, [2S-[N(1R*,2R*),2R*,4R*,5R*]]-, monoacetate (salt); or Ac-LVA-He-Amp; or IVA-LVA-Ile-Amp. Boc-Phe-His-Cha psi[CHOHCHOH]Val-Ile-Amp; or L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[l-(cyclohexylmethyl)-2,3- dihydroxy-5-methyl-4-[[[2-meihyl-l-[[(2-pyridinylmemyl)ammo]C-UTX)nyl]butyl]-ur_ino]car- bonyl]hexyl]-, [lS-[lR*,2S*,3S*,4S*(lR*.2R ,,t )]]-; or BOC-Phe-His-CVD-He-Amp: L-Histidinamide, N-[(l , l-dimethylethoxy)caιτx)nyl]-L-phenylalanyl-N-[2- hydroxy-l-(2-methylpropyl)-5-[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]- butyl]amino~5-oxo-4-(phenylmethyl)pentyl]-,[lS-[lR*,2R*,4S*,5(lR*,2R*)]]-;orBoc- Phe-His-LPA-He-Amp; L-Histidinamide, N-[(l,l-dimethylethoxy)carbonyl]-L-phenyla-anyl-N-[4- (cyclohexylmethyl)-2-hydroxy- 1 -(2-methylpropyl)-5-[[2-methyl-l -[[(2-pyridinylmethyl)- amino]carbonyl]butyl]amino]-5-oxopentyl]-, [1S-[1R*,2R*,4S*,5(1R*,2R*)]]-; or Boc- Phe-His-LCA-Ile-Amp; L-Talonamide, 6-cyclohexyl-2,5,6-trideoxy-5-[N-[N-[(l , 1-dimethyleth- oxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-2-(l-methylethyl)-N-[2-methyl-l-[[(2- pyridinylmethyl)amino]carbonyl]butyl]-, [S-(R*,R*)]-; or Boc-Phe-His-CVD'-He-Amp; L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N- (2,3-dihydroxy-5-memyl-l-(2-methylpropylH-[[(2-methyl-l-[[(2-pyridinylmethyl)amino]- carbonyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*,2S*,3R*,4S*(lR*,2R*)]]-;orBoc-Phe- His-LVDA'-Ile-Amp; L-Histidinamide, N-[[5-(dimethylamino)-l-naphthalenyl]sulfonyl]-L- phenylalanyl-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinyl- me yl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-, [1S-[1R*,2R*,4R*(1R*,2R*)]]-; or DANS-Phe-His-LVA-Ile-Amp; L-Histidinamide, L-phenylalanyl-N-[2-hydroxy-5-methyl-l-(2-methylpro- pyl)-4-[[[2-methyl- 1 -[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]- , [1S-(1R*,2R*,4R*(1R*,2R*)]]- or H-Phe-His-LVA-He-Amp; L-Valinamide, L-phenylalanyl-N-[2-hydroxy-5-methyl-l-(2-methylpropy- l)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]caτbonyl]hexyl]-, [1S-[1R*,2R*,4R*(1R*,2R*)]]-; or H-Phe-Val-LVA-He-Amp; L-Valinamide, L-valyl-N-[2-hydroxy-5-methyl- 1 -(2-methylpropyl)-4-[[[2- methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-, [1S- [1R*,2R*,4R*(1R*,2R*)]]-, diacetate (salt); or H-Val-Val-LVA-Ile-Amp; or L-Valinamide, N-acetyl-L-valyl-N-[2-hydroxy-5-methyl-l-(2-methylprop- yl)-4-[[[2 -methyl- 1 -[[(2-pyridinylmethyl)amino]carrx)nyl]butyl]anύno]carbonyl]hexyl]- , [1S-[1R*,2R*,4R*(1R*,2R*)]]-, monoacetate (salt); or Ac-Val-Val-LVA-Ile-Amp. Nα-[(2S,4S,5S)-5-[[Nα[(S)-l-Acetoxy-l-benzyl)methylcarbonyI]-L- histidyl]amino]-4-hydroxy-7-methyl-2-(l -methylethyl)- 1 -oxooctyl]-N-[2-pyridyl)ethyl] -L-isoleucinamide; or AcO-Phe-His-LVA-He-NH-fCH^^pyridine. 4-Mo holinebutanamide, β-hydroxy-N-[2-[[2-hydroxy-5-methyl-l-(2- memylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylme yl)-mιino]ca__bonyl]butyl]am o]ca-ix)nyl- ]hexyl]amino]- 1 -(lH-imidazol-4-ylmethyl)-2-oxoethyl]-α-( 1 -naphthalenylmethyl)- τ-oxo- , [lS-[lR*[R*(αS*,βR*)],2R*,4R*(lR*,2R*)]]-; lH-__midazole-4-propanamide, α-[[[5-(dime_hyl_unino)-l-naphthalenyl]su- lfonyl]amino]-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinyl- m e th y l ) a mi n o ] c arb o n y l ] b u t y l ] a m i n o ] c arb o n y l ] h ex y l ] - , [ 1 S - [1R*(R*),2R*,4R*(1R*,2R*)]]-; or DANS-His-LVA-He-Amp; lH-Imidazole-4-propanamide, c_-amino-N-[2-hydroxy-5-methyl-l-(2- ]hexyl]-, [1S-[1R*(R*),2R*,4R*(1R*,2R*)]] or H-His-LVA-He-Amp; Octanamide, 5-[P-(acetylanιino)-3-memyl-l-oxobutyl]__ι ino]-4-hydroxy- 7-methyl-2-(l-methylethyl)-N-[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]-, [2S-[N(1R*,2R*),2R*,4R*,5R*(R*)]]-, monoacetate (salt); or Ac-Val-LVA-Ile-Amp; Ac-Asn-LVA-Ile-Amp; Nα-[(2S.4S,5S)-5-[[(S)-(l-Hydroxy-l-benzyl)methylcarbonyl]amino]-4- hydroxy)-7-memyl-2-(l-me ylethyI)-l-oxooctyl]-N-(2-pyridinylmemyl)-L-isoleucinamide; or HO-Phe-LVA-Ile-Amp; lH-Imida_x>le -propanamide,N-[2-hydroxy-5-methyl-l-(2-methylpropyl)- 4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-α-[(2- hydroxy-l-oxo-3-phenylpropyl)amino]-,[lS-[lR*p.*(R*)],2R*,4R*(lR*,2R*)]]-, 2- hydroxy-1 ,2,3-propanetricarboxylate (12) (salt) orphenyl-CH 2 -CH(OH)-C(O)-His-LVA- Ile-Amp; L-α-Glutamine, N/u2/d-[N-[[l , l-dimethylethoxy)carbonyl]-L-phenylal- anyl]-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinyl- methyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*,2R*4R*(lR*,2R*)]]- ,monacetate (salt) or BOC-Phe-Glu-LVA-Ile-Amp; L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-3-(2-pyridinyl)alanyl- N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]c- aιtonyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]-orBOC-2- Py-Ala-His-LVA-Ile-Amp; L-.alpha.-Asparagine, N/u 2/d-[N-[(l .l-dimethylethoxy)carbonyl]-L- phenylalanyl]-N-[2-hydroxy-5-methyl- 1 -(2-methylpropyl)-4-[[2-methyl- 1 -[[(2-pyridinylme- thyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*,2R*,4R*(lR*,2R*)]]- ,monoacetate (salt) or BOC-Phe-Asp-LVA-Ile-Amp; U-77808E L-.alpha.-Glutamine, N-[l , l-dimethylethoxy)carbonyl]-L-phenylalanyl- N0[l-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amin- o]carbonyl]butyl]amino]carbonyl]hexyl]]-,[lS-[lR*,2R*,4R*(lR ,,, ,2R ,,t )]]-, monoacetate (salt) or BOC-Phe-Glu-CVA-He-Amp; L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N- [3 , 3-difluoro-2-hydroxy-4-[[2-methyl- 1 -[[(2-pyridinylmethyl)amino]carbonyl]butyl]am- ino]-4-oxo-l-(phenylmethyl)butyl]-orCH 3 -C(O)-O-CH(benzyl)-C(O)-His-LVA-Ile-Amp; L-Glycyl-L-histidyl-5 S -amino-6-cyclohexyl-3R , 4R-dihy droxy-2R- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Gly-His-C V A-He- Amp ; L-Glycyl-L-histidyl-5S-__mincH2R-benzyl-6-cyclohexyl-3R,4R-_lihydroxy- hexanoyl-L-isoleucyl-2-ρyridylmethylamide or Gly-His-CPD-Ile-Amp; 5-Quinolinylhydroxyace-yl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy- 2S-isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Qoa(b)-His-C V A-Ile- Amp ; Quinolinylhydroxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy- 2S-isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Qoa(a)-His-CVA-Ile-Amp; N-tert-Butyloxyc --- _tx)nyl-L-alanyl-5S-amino-6-cyclohexyl-4S-hydrOxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Boc-Ala-CVA-He-Amp; N-tert-Butyloxycarr )nyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy- ' 2S-isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or BOC-His-CVA-He-Amp; Benzyloxycarbonyl-L-alanyl-L-alanyl-5S-amino-6-cyclohexyl-4S- hydroxy-2S-isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamida_)iCBZ-Ala-Ala-CVA- Ile-Amp; L-Histidinamide, N-[(l,l-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[4- [[[2-[(2,6-diamino-4-pyrimidinyl)amino]ethyl]amino]carbonyl]-2-hydroxy-5-methyl-l-(2- methylpropyl)hexyl]-,[lS-(lR*,2R*,4R*)]- or BOC-Phe-His-LVA-(2,6-di__π_ino^pyrime- dinyl)amino-ethylamino; Gly-CVD-He-Amp; and Gly-CPD-He-Amp; to prepare a medicament for inhibiting a retrovirsus in a human cell infected with said retrovirus. 12. A compound selected from the group consisting of: Cyclohexanehexanamide, δ-(acetylamino)- τ-hydroxy-α-( 1 -methylethyl)- N-[2-methyl- 1 -[[(pyridinylmethyl)amino]carbonyl]butyIj S-[N( IR* ,2R*) ,αR* , TR* , δR- *]]-; or Ac-CVA-Ile-Amp; Octanamide, 5-(acety_amino)-4-hydroxy-7-methyl-2-(l-methylethyl)-N-[2- methyl-l-[[(2-pyridinylmethyl)_imino)caibonyl]butyl]-, [2S-[N(1R*,2R*),2R*,4R*,5R*]]-, monoacetate (salt); or Ac-LVA-He-Amp; L-Valinamide, L-phenylalanyl-N-[2-hydroxy-5-methyl-l-(2-methylpropy- l)-4-[[[2-methyl- 1 -[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]- , [1S-[1R*,2R*,4R*(1R*,2R*)]]-; or H-Phe-Val-LVA-He-Amp; Octanamide, 5-f[2-(acety_am o)-3-methyl-l-oxobutyl]amino]- -hydroxy- 7-memyl-2-(l-me ylethyl)-N-[2-memyl-l-[[(2-pyridinylmemyl)amino]carbonyl]butyl]-, [2S-[N(1R*,2R*),2R*,4R*,5R*(R*)]]-, monoacetate (salt); or Ac-Val-LVA-He-Amp; L- Valinamide, L-valyI-N-[2-hydroxy-5-methyl- 1 -(2-methylpropyl)-4-[[[2- methyl-l-[[(2-pyridinylmethyl)amino]carbonyI]butyl]amino]carbonyl]hexyl]-, [1S- [1R*,2R*,4R*(1R*,2R*)]]-. diacetate (salt); or H-Val-Val-LVA-Ile-Amp; Ac-Asn-LVA-Ile-Amp; L-Valinamide, N-acetyl-L-valyl-N-[2-hydroxy-5-methyl-l-(2-methylprop- yl)-4-[[[2-methyl- 1 -[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]- , [1S-[1R*,2R*,4R*(1R*,2R*)]]-, monoacetate (salt); or Ac-Val-Val-LVA-Ile-Amp; or N-[(2S ,4S ,5S)-5-[Nα-[Nα-(tert-Butoxycarbonyl)-O-methy l-L-tyrosyl]-L- _ϋstidyl]amino]-4-hydroxy-7~methyl-2-phenylmethyl- 1 -oxooctyI]-N-[(S)-2-hydroxypropyl]- amine; or Boc-OMeTyr-His-LPA-NH-CH 2 -CH(CH 3 )(OH). 13. A compound of formula I X-C 8 -D 9 -E 10 -F π -Gι 2 -Z I f) -NH-(CH 2 ) n -CH(OH)-C r C 5 alkyl, or g) -NH-(CH 2 ) n -NH-(2 , 6-diamino-4-pyrimidinyl) . wherein n is O to five, inclusive. 14. A compound of claim 13. wherein X is a) 1-naphthyloxyacetyl, b) p-toluene-sulfonyl, c) phenyloxyacetyl, or d) 3-pyridinyl-methylcarbonyl; wherein C g is absent; wherein D 9 is His; wherein Eι 0 -F π is CVA; wherein G !2 is a) absent, or b) He; wherein Z is a) Amp, _ ' b) Amp-NO c) L-lysine, or d) -NH-(CH 2 ) 2 -NH-2-pyridine. 15. A compound of claim 14 selected from the group consisting of: Nc.-[(2S, 4S, 5S)-5-[N-I Iα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide, pyridine N-oxide or NOA-His-CVA-Ile-Amp-NO; Nα-[(2S , 4S , 5S)-5-[N-[Nα-(f-toluenesulfonyl)-L-histidyl]amino]-6-cyclohexyl- 4-hydroxy-2-isopropyl- l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide or p- Tolunesulfonyl-His-CVA-He-Amp; Nα-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide or NOA-His-CVA-He-Amp; Nα-[(2S, 4S, 5S)-5-[N-[Nc.-(Phenoxymethylcarbonyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide, pyridine N-oxide or POA-His-CVA-He-Amp-NO; N -[(2S,4S^S)-5-[N-[N -(p-Toluenesulfonyl)-L-histidyl]amino]-6-cyclohexyl- 4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide,pyridineN- oxide or p-Toluenesulfonyl-His-CVA-Ile-Amp-NO; Ne-[(2S , 4S , 5S)-5-[N-[Nc_-( 1 -Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-L-lysine,triflouroacecticacidsaltorNOA- His-CVA-L-lysine,triflouroacetic acid salt; N-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-[2-(2-pyridinylamino]ethyl]-amine or NOA-His-CV A-NH-(CH 2 ) 2 -NH-(2-pyridine) ; N-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-[2-(2-pyridinylamino)]ethyl]amine,- pyridine N-oxide or NOA-His-CVA-NH(CH 2 ) 2 -NH-(2-pyridine); Nc_-[(2S, 4S, 5S)-5-[N-[Nα-(l-Naphthalenyloxyacetyl) (2-ρyridinyl)alanyl]- amino]-6-cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L- isoleucinamide or NOA-His-CVA-He-Amp; Nα-[(2S,4S^S)-5-[ f-[ fα-[(3-Pyridinyl)-methylcarbonyl]-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-(2-pyridinylmethyl)-L-isoleucinamide or (3-pyridinyl)-methyl-carbonyl-His-C V A-Ile- Amp ; Ne-[N 2 -[(2S,4S,5S)-5-[N-[Nc_-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyI]-L-isolencyl]-L-lysine,triflouroaceticacid salt or NOA-His-CVA-He-L-lysine, trifluoroacetic acid salt; N -[(2S, 4S, 5S)-5-[N-[Nc_-(l-Naphthalenyloxyacetyl)-L-histidyl]amino]-6- cyclohexyl-4-hydroxy-2-isopropyl-l-oxohexyl]-N-[2-(2-pyridinylamino)ethyl]-L- isoleucinamide or NOA-His-CV A-He-NH-(CH 2 ) 2 -NH-(2-pyridine). 16. A compound of claim 13. wherein X is a) phenyl-CH 2 -CH(OH)-C(O)-, b) phenyloxyacetyl, c) t-butyloxycarbonyl, d) lH-indol-2-ylcarbonyl, e) 2-pyridyl-acetyl, f) 4-pyridyl-acetyl, g) 4-pyridyl-CH 2 -O-C(O)-, 17. A compound of claim 16 selected from the group consisting of: lH-Imidazole-4-prorjanan_ide,N-[2-hyd_oxy-5-methyl-l-(2-methylpropyl)-4-[[[2- methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-α-[(2- hydroxy-l-oxo-3-phenylpropyl)amino]-,[lS-[lR*[R*(R*)],2R*,4R*(lR*,2R*)]]-, 2- hydroxy-l,2,3-propanetricarboxylate(l 2) (salt) orρhenyl-CH 2 -CH(OH)-C(O)-His-LVA- He-Amp; lH-Irnida_»le-4-propanamide,N-[2-hydroxy-4-[[[l-[[(2-hydroxy-2-phenylethyl)- amino]carbonyl]-2-methylbutyl]amino]carbonyl]-5-methyl-l-(2-methylpropyl)hexyl]- _.- [(phenoxyacetyl)amino]-,monoacetate (salt) or POA-His-LVA-Ile-NH-CH 2 -CH(OH)- phenyl; L-α-Glut__mine,N/u2/d-[ -[[l , l-dimethylethoxy)c__rbonyl]-L-phenylalanyl]-N- [2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2 -methyl- 1 -[[(2 -pyridinylmethyl)amino]- cartionyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*,2R*4R*(lR*,2R*)]]-,monacetate(salt) or BOC-Phe-Glu-LVA-Ile-Amp; Pentanoic acid, 5-[[l-(cyclohexylmethyl)-2-hydroxy-4-[[(2-hydroxypropyl)- amino]carbonyl]-5-methylhexyl]amino]-5-oxo-4-[(phenoxyacetyl)amino]- or POA-Glu- ' CVA-NH-CH 2 CH(CH 3 )(OH); lH-Imidazole-4-propanamide, N-[l-(cyclohexylmethyl)-2-hydroxy-4-[[(2- hydroxypropyl)amino]carbonyl]-5-methylhexyl]α-[(phenoxyacetyl)amino]-, monoacetate (salt) or POA-His-CVA-NH-CH 2 -CH(OH)(CH 3 ); Pentanoic acid, 5-[[l-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[2-methyl-l- [[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]amino]-4-[(lH-indol-2- ylcarbonyl)aιmno]-5-oxo-,[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]βriH-indol-2-yl-carbonyl- Glu-CVA-ϋe-Amp; L-. alpha. -Glutamine, N-[ 1 -(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[2- methyl-l-[[(2-pyridinylmemyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-N/u 2/d-L- phenylalanyl-, [1S-[1R*,2R*,4R*(1R*,2R*)] , bis(trifluoracetate) (salt) or Phe-Glu- CVA-He-Amp; 2-Pyridineacetamide, N-[2-[[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2- methyl-l-[[(2-pyridinylmemyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]amino]-l-(lH- imidazol-4-ylmethyl)-2-oxoethyl]-[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-or (2-Pyridyl)acetyl- His-LVA-Ile-Amp; 4-Pyridineacetamide, N-[2-[[2-hydroxy-5-methyl-l-(2-methylpropyl)-4- [[[2methyl-l-[[(2-pyridinylmemyl)amino]carrx>nyl]butyl]amino]carbonyl]hexyl]amino]-l- (lH-imidazol-4-ylmethyl)-2-oxoethyl]-[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-or (4- Pyridyl)acetyl-His-LVA-He-Amp; L-Histidinamide,N-[(l , l-dimethylethoxy)carbonyl]-3-(2-pyridinyl)alanyl-N-[2- hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carbo- nyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]-or BOC-2-Py- Ala-His-LVA-He-Amp; L-Histidinamide, N-[(l , l-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[4-[[[2- [(2,6-<iiamino-4-pyrimidinyl)amino]ethyl]amino]carbonyl]-2-hydroxy-5-methyl-l-(2- methylpropyl)hexyl]-,[lS-(lR*,2R*,4R*)]- or BOC-Phe-His-LVA-(2,6-diamino-4-pyrimi- dinyDamino-ethylamino; L-.alpha.-Asparagine,N/u2/d-[N-[(l ,l-dimethylethoxy)carbonyl]-L-phenylala- nyl]-N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[2-methyl-l -[[(2-pyridinylme- thyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-,[lS-[lR*.2R*,4R*(lR*,2R*)]]- , monoacetate (salt) or BOC-Phe-Asp-LVA-Ile-Amp; lH-Indole-2-carboxamid_^.-[2-([2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[2- methyl-l-[[(2-pyridinylmethyl)amino]carbonyl]butyl]carbonyl]hexyl]amino]-l-(lH- imidazol-4-ylmethyl)-2-oxoethyl]-,[lS-[lR*(R*),2R*,4R*(lR*,2R*)]]-;-(Indolyl-2- carbonyl)-His-LV A-He- Amp ; L-.alpha.-Glutamine, N-[l, l-dimethylethoxy)carbonyl]-L-phenylalanyl-NO[l- (cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[2-methyl-l-[[(2-pyridinylmethyl)amino]carb- onyl]butyl]amino]carbonyl]hexyl]]-,[lS-[lR*,2R*,4R*(lR*,2R*)]]-, monoacetate (salt) or BOC-Phe-Glu-CVA-Ile-Amp; 2,5,11,14-Tetraazapentadecanoic acid, 7-hydroxy-3-(lH-imidazol-4-ylmethyl)-9- (l-methylethyl)-12-(l-methylpropyl)-6-(2-methylpropyl)-4, 10, 13-trioxo-15-(2-pyridinyl)- ,4-pyridinylmethyl ester, [3S-[3R*,6R*,7R*,9R*,12R*(R*)]]-; lH-Imidazole-4-propanamide, N-[2-hydroxy-5-methyl-l-(2-methylprσpyl)-4-[[[2- memyl-l-[[(2-pyridinylmethyl)anιino](»_ κ3nyl]butyl]amino]c__rbonyl]hexyl]-α-[(l-oxo-3- phenoxypropyl)amino]-,[lS-riR*(R*),2R*,4R*(lR*,2R*)]]-,orPhenoxypropionyl- His-LVA-He-Amp; lH-Imidazole-4-prorj^mamide,N-[2-hydroxy-5-memyl-l-(2-methylp_τjpyl)-4-[[[2- methyl-l-[[[(2-pyridinylmethyl)am o[ca_^nyl[butyl[am__no[carbonyl[hexyl]-o-[(l-oxo- 3phenyl-2-propenyl)amino]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]]-orphenyl-CH=CH- C(O)-His-LVA-He-Amp; lH-Imidazole- -propanamide,N-[2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2- methyl-l-[[[(2-pyridinylmethyl)aι nc[cart>onyl]|pu^ phenyl-3-butenyl)amino]-,[lS-[lR*[R*(E)],2R*,4R*(lR*,2R*)]j- or phenyl-CH=CH- CH 2 -C(O)-His-LVA-He-Amp; 2,5,11, 14-Tetraazapentadecanoic acid, 7-hydroxy-3-(lH-imidazol-4-ylmethyl)-9- (l-methylethyl)-12-(l-methylpropyl)-6-(2-methylpropyl)-4, 10, 13-trioxo-15-(2-pyridinyl)- ,3-phenyl-2-propenyl ester, [3S-[1(E),3R*,6R*,7R*,9R*,12R*(R*)]]- or phenyl- CH = CH-CH 2 -O-C(O)-His-LVA-He-Amp; and lH-Imida-∞le-4-prorjanamide,N-[2-hydιoxy-5-methyl-l-(2-methylpropyl)-4-[I 2- methyl- 1 -[[(2-pyridinylmeth yl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-α-[[(2- phenyle_henyl)sulfonyl]amino]-,[lS-[lR*[R*(E)] ? 2R*,4R*(lR*,2R*)]]-or phenyl- (CH 2 )-SO 2 -His-LVA-He-Amp; 18. A compound of claim 13. wherein X is a) t-butyloxycarbonyl , b) (HO) acetyl, c) hydrogen, d) phenyloxyacetyl, e) 1 -naphthyloxyacetyl , f) 5-quinolinylhydroxyacetyl, g) 4-quinolinylhydroxyacetyl, or ) 2-quinolinylcarbonyl; wherein C g is a) absent b) Phe, or c) -NH-CHAO)-; wherein D 9 is a) His, b) Asn, or c) -NH-CH 2 C(O)-; wherein E 10 -Fn is a) CVD, b) LVD, c) CPD, d) CLD, e) CCD, f) CcD, g) PPD, h) LID, i) CVA, j) LLd, or k) LLD; 19. A compound of claim 18 selected from the group consisting of: N-tert-Butyloxycaιbonyl-L-phenylalanyl-L-histidyl-5S-amino-3R,4R-dihydroxy- 2R-isopropyl-7-methyl-octanoyl-2S-methylbutylamide or BOC-Phe-His-LVA-Mba; Hydroxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isopropyl-hexanoyl-L-isoleucy 1-2-pyridylmethylamide or (HO) Ac-His-C V A-Ile- Amp ; L-Glycyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R-isopropyl- hexanoyl-L-isoleucyl-2-pyridylmethylamide or Gly-His-CVA-He-Amp; Hydroxyacetyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R-dihydroxy- hexanoyl-L-isoleucyl-2-pyridylmethylamide or (HO)Ac-His-CPD-Ile-Amp; Hydroxyacetyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R-dihydroxy- hexanoyl-L-isoleucyl-2-pyridylmethylamide, N-oxide or (HO)Ac-His-CPD-He-Amp; Phenoxyacetyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R-dihydroxy- hexanoyl-L-isoleucyl-2-pyridylmethylamide or POA-His-CPD-Ile-Amp; L-Glycyl-L-histidyl-5S-amino-2R-benzyl-6-cyclohexyl-3R,4R-dihydroxy- hexanoyl-L-isoleucyl-2-pyridyImethylamide or Gly-His-CPD-Ile-Amp; Phenoxyacetyl-L-_ύstidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R-isσpropyl- hexanoyl-L-isoleucyl-2-pyridylmethylamide or POA-His-CVA-He-Amp; l-Naphtoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isobutyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-CLD-He-Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-2R-cyclohexylmethyl- 3R,4R-dihydroxy-hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-CCD-He- Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-2R-benzyl-3R,4R-dihydroxy-6-phenyl- hexanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-PPD-He-Amp; l-Naphthoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R- isopropyl-hexanoyl-L-isoleucyl-2-pyridinylamino-ethylamideorNOA-His-CVD-Ile-Apr: l-Naphthoxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-2S-cyclohexylmethyl- 3R,4R-dihydroxy-hexanoyl-L-i_ leucyl-2-pyridylmethylamide or NOA-His-CcD-fle-Amp ; l-Naphthoxyacetyl-L-histidyl-5S-amino-3S-4S-dihydroxy-2S-isobutyl-7-methyl- octanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-Lld-He-Amp; 5-Quinolinylhydroxyacetyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Qoa(b)-His-CV A-He- Amp; 4-Quinolinylhydroxyacetyl-L-lustidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Qoa(a)-His-CVA-Ile-Amp; l-Naphthoxyacetyl-L-h_-stidyl-5S--unino-3R-4R-dihydroxy-2S-isobutyl-7-methyl- octanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-LLd-He-Amp; l-Naphthoxyacetyl-L-h_-stidyl-5S-ammo-3S-4R-dihydroxy-2S-isobutyl-7-methyl- octanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-LLd-He-Amp; l-Naphmoxyacetyl-L-Wstidyl-5S-am_no-3R-4R-dihydroxy-2R-isobutyl-7-methyl- octanoyl-L-isoleucyl-2-pyridylmethylamide or NOA-His-LLD-He-Amp; 2-Quinolinylcaιtκ)nyl-5S-amino-6-cyclohexyl-3R,4R-dihydroxy-2R-isopropyl- hexanoyl-L-irøleucyl-2-pyridinylamino-ethylamide or Qc-Asn-CVD-He-Apr; L-Glycyl-5S-an_ino-6-cyclohexyl-3R,4R-dihydroxy-2R-isopropyl-hexanoyl-=L- isoleucyl-2-pyridylmethylamide-or Gly-CVD-He-Amp; L-Glycyl-5S-amino-2R-benzyl-6-cyclohexyl-3R , 4R-dihydroxy-hexanoyl-L- isoleucyl-2-pyridyl-methylamide or Gly-CPD-He-Amp. 21. A compound of claim 20 selected from the group consisting of: N-tert-Butyloxycarbonyl-L-alanyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or Boc-Ala-CV A-He- Amp ; N-tert-Butyloxycarbonyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or BOC-His-CVA-He-Amp; Quinolinyl-2-carbonyl-L-histidyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or QC-His-CV A-He- Amp; Quinolinyl-2-carbonyl-L-asparaginyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or QC-Asn-CV A-He- Amp; Benzyloxycarbonyl-L-alanyl-L-alanyl-5S-amino-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucyl-2-pyridylmethylamide or CBZ- Ala- Ala-CV A-He- Amp ; l-Naphthalenyloxyacetyl-L-histidyl-5S-amine-6-cyclohexyl-4S-hydroxy-2S- isopropyl-hexanoyl-L-isoleucylamide or Noa-His-CVA-fle-NH 2 ; and POA-His-CVA-NH-(CH 2 ) 4 -CH(CONH)(NH 2 ). 22. A compound of claim 13 wherein X is a) 1-naphthyloxyacetyl, or b) 5-(triethyleneglycolmonomethyl ether) naphthoxyacetyl; wherein C g is absent; wherein D 9 is Asp; wherein E,o-F u is CVA; wherein G n is He; wherein Z is Amp. 23. A compound of claim 22 selected from the group consisting of: L-Asparaginamide, l-(naphthoxy)acetyl-N-[2-hydroxy-5-methyl-l-(2-methyl- propyl)-4-[[[2-methyl-l-[[[2-(N-oxido)pyridinylmethyl]amino]carbonyl]butyl]amino]carb- onyl]hexyl]-N-alpha-methyl-, [1S-[1R*,2R*,4R*(1R*,2R*)]]- or NOA-Asp-CVA-Ile- Amp; L-Asparaginamide, [5-(triethyleneglycolmonomethylether)naphthoxy]acetyl-N- [2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[[2-(N-oxido)pyridinyl- methyl]ammo]carbonyl]butyl]amino]caτbonyl]hexyl]-N-alpha-methyl-, [1S-[1R*,2R*,4R*- (lR*,2R*)]]-or 5-(triethyleneglycol monomethyl ether-NOA-Asp-CVA-He-Amp; and L-Asparaginamide, [4-(triethyleneglycolmonomethylether)naphthoxy]acetyl-N- [2-hydroxy-5-methyl-l-(2-methylpropyl)-4-[[[2-methyl-l-[[[2-(N-oxido)pyridinyl- memyl]an ino]C-_rbonyl]butyl]ammo]caι_3onyl]hexyl]-N-alpha-methyl- , [lS-[ IR* ,2R* , - 4R*(1R*,2R*)]]- or 4-(triethyleneglycol monomethyl ether)-NOA-Asp-CVA-Ile-Amp.

Inventors: HEINRIKSON ROBERT LEROY, HESTER JACKSON B JR, HUI JOHN ON-TING, SAWYER TOMI KIM, SCHOSTAREZ HEINRICH JOSEF, TARPLEY WILLIAM GARY, TEN BRINK RUTH ELIZABETH, THAISRIVONGS SUVIT, TOMASSELLI ALFREDO GUISEPPE, HEINRIKSON, ROBERT, LEROY, HESTER, JACKSON, B., JR., HUI, JOHN, ON-TING, SAWYER, TOMI, KIM, SCHOSTAREZ, HEINRICH, JOSEF, TARPLEY, WILLIAM, GARY, TEN BRINK, RUTH, ELIZABETH, THAISRIVONGS, SUVIT, TOMASSELLI, ALFREDO, GUISEPPE
Applicants: UPJOHN CO, THE UPJOHN COMPANY
Application year: 1990
Main classification: A61K37
IPC codes: A61K31, A61K38, A61P31, C07C237, C07D213, C07D233, C07K5, C07K14